<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22376" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gout</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fenando</surname>
            <given-names>Ardy</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rednam</surname>
            <given-names>Manjeera</given-names>
          </name>
          <aff>Katuri Medical College and Hospital, Guntur, India</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gujarathi</surname>
            <given-names>Rahul</given-names>
          </name>
          <aff>University of Florida Health, Jacksonville, FL</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Widrich</surname>
            <given-names>Jason</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ardy Fenando declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manjeera Rednam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rahul Gujarathi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jason Widrich declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22376.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Gout is one of the most common causes of chronic inflammatory arthritis in the United States, characterized by monosodium urate (MSU) monohydrate crystals deposition in the tissues. Gout was first recognized even before the common era. Hence, it is arguably the most understood and manageable disease among other rheumatic diseases. This activity reviews the evaluation and management of gout and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical and biochemical markers of gout, including hyperuricemia and monosodium urate crystals, for accurate diagnosis.</p></list-item><list-item><p>Screen for gout risk factors, hyperuricemia, and associated comorbidities, especially in at-risk patients.</p></list-item><list-item><p>Select appropriate urate-lowering therapies, anti-inflammatory agents, and pain management strategies tailored to individual patient profiles.</p></list-item><list-item><p>Collaborate with healthcare providers to facilitate comprehensive care, ensuring consistent messaging and therapy coordination.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22376&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22376">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22376.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gout, once known as the "disease of kings and king of diseases," is among the most prevalent etiologies of chronic inflammatory arthritis in the United States, characterized by monosodium urate (MSU) monohydrate crystals deposition within tissues.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref><xref ref-type="bibr" rid="article-22376.r2">[2]</xref>&#x000a0;Hippocrates first described gout in ancient Greece; hence, it is the most understood and manageable disease among all rheumatic diseases.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref><xref ref-type="bibr" rid="article-22376.r4">[4]</xref></p>
        <p>Gout is characterized biochemically by extracellular fluid urate saturation, which is reflected by hyperuricemia in the blood, with plasma or serum urate concentrations exceeding 6.8 mg/dL (approximately 400 &#x000b5;mol/L); this level is the approximate limit of urate solubility.<xref ref-type="bibr" rid="article-22376.r5">[5]</xref>&#x000a0;The clinical manifestations of gout may include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute gout flare (recurrent flares of inflammatory arthritis)</p>
          </list-item>
          <list-item>
            <p>Chronic gouty arthropathy</p>
          </list-item>
          <list-item>
            <p>Accumulation of urate crystals in the form of tophaceous deposits</p>
          </list-item>
          <list-item>
            <p>Uric acid nephrolithiasis</p>
          </list-item>
          <list-item>
            <p>Chronic nephropathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22376.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of gout is usually multifactorial, including genetic predisposition, medical comorbidities, and dietary factors. In rare cases, a single genetic defect may be responsible for causing gout, usually associated with other medical complications.&#x000a0;Irrespective of&#x000a0;the underlying trigger, the result&#x000a0;involves elevated serum uric acid, which&#x000a0;can manifest as clinical gout in certain individuals.</p>
        <p>
<bold>Genes Associated with Gout</bold>
</p>
        <p>The heritability of hyperuricemia and gout is about 73% and about 40% to 50% of patients have a family history of gout.<xref ref-type="bibr" rid="article-22376.r6">[6]</xref>&#x000a0;Genes associated with gout fall into&#x000a0;4 categories (see <bold>Table.&#x000a0;</bold>Genes Associated With Gout).<xref ref-type="bibr" rid="article-22376.r6">[6]</xref><xref ref-type="bibr" rid="article-22376.r7">[7]</xref></p>
        <table-wrap id="article-22376.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.&#x000a0;Genes Associated With Gout</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 268px;" rowspan="1" colspan="1">
<bold>Gene function</bold>
</td>
                <td style="width: 125.688px;" rowspan="1" colspan="1">
<bold>Gene name</bold>
</td>
                <td style="width: 636.312px;" rowspan="1" colspan="1">
<bold>Gene product</bold>
</td>
                <td style="width: 171px;" rowspan="1" colspan="1">
<bold>Location</bold>
</td>
              </tr>
              <tr>
                <td style="width: 268px;" rowspan="1" colspan="1">
<bold>Production of uric acid</bold>
</td>
                <td style="width: 125.688px;" rowspan="1" colspan="1">
<p><italic toggle="yes">HPRT1</italic></p>
<p><italic toggle="yes">PRPS1</italic></p>
<p><italic toggle="yes">ALDH16A1</italic></p>
</td>
                <td style="width: 636.312px;" rowspan="1" colspan="1">
<p>Hypoxanthine guanine phosphoribosyltransferase (HGPRT)</p>
<p>Phosphoribosyl pyrophosphate&#x000a0;synthetase 1 (PRPPS)</p>
<p>Acetaldehyde dehydrogenase 16 family A1</p>
</td>
                <td style="width: 171px;" rowspan="1" colspan="1">
<p>Xq26.2-q26.3</p>
<p>Xq22.3</p>
<p>19q13.33</p>
</td>
              </tr>
              <tr>
                <td style="width: 268px;" rowspan="1" colspan="1">
<bold>Reabsorption of uric acid in renal tubule</bold>
</td>
                <td style="width: 125.688px;" rowspan="1" colspan="1">
<p><italic toggle="yes">SLC22A11</italic></p>
<p><italic toggle="yes">SLC22A12</italic></p>
<p><italic toggle="yes">SLC22A13</italic></p>
<p><italic toggle="yes">SLC2A9</italic></p>
</td>
                <td style="width: 636.312px;" rowspan="1" colspan="1">
<p>Organic anion transporter 4 (OAT4)</p>
<p>Urate transporter 1 (URAT1)</p>
<p>Organic anion Transporter 10 (OAT10)</p>
<p>Glucose transporter 9 (GLUT9)</p>
</td>
                <td style="width: 171px;" rowspan="1" colspan="1">
<p>11q13.1</p>
<p>11q13.1</p>
<p>3p22.2</p>
<p>4p16.1</p>
</td>
              </tr>
              <tr>
                <td style="width: 268px;" rowspan="1" colspan="1">
<bold>Excretion of uric acid in renal tubule</bold>
</td>
                <td style="width: 125.688px;" rowspan="1" colspan="1">
<p><italic toggle="yes">ABCG2</italic></p>
<p><italic toggle="yes">ABCC4</italic></p>
<p><italic toggle="yes">SLC22A6</italic></p>
<p><italic toggle="yes">SLC22A8</italic></p>
<p><italic toggle="yes">SLC17A1</italic></p>
<p><italic toggle="yes">SLC17A3</italic></p>
<p><italic toggle="yes">SLC17A4</italic></p>
<p><italic toggle="yes">SLC2A12</italic></p>
</td>
                <td style="width: 636.312px;" rowspan="1" colspan="1">
<p>ATP-binding cassette transporters G2 (ABCG2)</p>
<p>Multidrug resistance protein 4 (MRP4)</p>
<p>Organic anion transporter 1 (OAT1)</p>
<p>Organic anion transporter 3 (OAT3)</p>
<p>Sodium-dependent phosphate transporter 17A1</p>
<p>Sodium-dependent phosphate transporter 17A3</p>
<p>Sodium-dependent phosphate transporter 17A4</p>
<p>Glucose transporter 12</p>
</td>
                <td style="width: 171px;" rowspan="1" colspan="1">
<p>4q22.1</p>
<p>13q32.1</p>
<p>11a12.3</p>
<p>11q12.3</p>
<p>6p22.2</p>
<p>6p22.2</p>
<p>6p22.2</p>
<p>6p23.2</p>
</td>
              </tr>
              <tr>
                <td style="width: 268px;" rowspan="1" colspan="1">
<bold>Other</bold>
</td>
                <td style="width: 125.688px;" rowspan="1" colspan="1">
<p><italic toggle="yes">PDZK1</italic></p>
<p><italic toggle="yes">GCKR</italic></p>
<p><italic toggle="yes">PKD2</italic></p>
<p><italic toggle="yes">SLC16A9</italic></p>
<p><italic toggle="yes">CARML1</italic></p>
<p><italic toggle="yes">SCGN</italic></p>
<p><italic toggle="yes">UMOD</italic></p>
<p><italic toggle="yes">ALDH2</italic></p>
</td>
                <td style="width: 636.312px;" rowspan="1" colspan="1">
<p>PDZ domain-containing 1 (scaffolding protein)</p>
<p>Glucokinase regulatory protein</p>
<p>Ion channels of transient receptor potential superfamily</p>
<p>Monocarboxylic acid transporter 9 (MCT9)</p>
<p>Myosin 1 connexin (CARMIL)</p>
<p>Seceragogin</p>
<p>Uromodulin</p>
<p>Aldehyde dehydrogenase 2</p>
</td>
                <td style="width: 171px;" rowspan="1" colspan="1">
<p>1q21.1</p>
<p>2p23.2</p>
<p>4q22.1</p>
<p>10q21.2</p>
<p>6p22.2</p>
<p>6p22.2</p>
<p>16p12.3</p>
<p>12q24.12</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Risk Factors</bold>
</p>
        <p>The final step of purine metabolism is the conversion of hypoxanthine to xanthine and then uric acid by xanthine oxidase, which then transforms allantoin by uricase. Allantoin has a much higher solubility than uric acid. Humans, other primates, giraffes, and Dalmatians possess gene&#x000a0;mutations&#x000a0;that result in the absence&#x000a0;of uricase production,<xref ref-type="bibr" rid="article-22376.r8">[8]</xref><xref ref-type="bibr" rid="article-22376.r9">[9]</xref>&#x000a0;a genetic mutation resulting in the inactivation of the uricase gene occurred about 25 million years ago. Simultaneously, there was an increase in URAT1 activity, responsible for uric acid excretion. About 20 million years ago, humans and other primates lost the ability to produce vitamin C,<xref ref-type="bibr" rid="article-22376.r9">[9]</xref>&#x000a0;leading to the emergence of the antioxidant theory&#x000a0;in which&#x000a0;uric acid replaced ascorbic acid as the main antioxidant.</p>
        <p>One unique aspect of this evolutionary process is the development of hyperuricemia in humans, making them the only known mammals to develop spontaneous gout. Hyperuricemia is the leading cause of gout,<xref ref-type="bibr" rid="article-22376.r1">[1]</xref><xref ref-type="bibr" rid="article-22376.r10">[10]</xref>&#x000a0;a condition where uric acid crystals accumulate in joints, causing inflammation and pain. Research has shown that individuals with higher&#x000a0;serum urate levels face an increased risk of&#x000a0;developing gout and&#x000a0;experiencing more frequent flare-ups over time.<xref ref-type="bibr" rid="article-22376.r11">[11]</xref><xref ref-type="bibr" rid="article-22376.r12">[12]</xref>&#x000a0;In a study involving over 2000 older adults with gout, those with serum urate levels exceeding 9 mg/dL were&#x000a0;3 times more likely to experience a flare over the next 12 months than those with levels below 6 mg/dL (see <bold>Table.&#x000a0;</bold>Relationship Between Serum Uric Acid Concentration and&#x000a0;Incident&#x000a0;Gout).<xref ref-type="bibr" rid="article-22376.r13">[13]</xref></p>
        <table-wrap id="article-22376.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Relationship Between Serum Uric Acid Concentration and&#x000a0;Incident&#x000a0;Gout&#x000a0;[12]</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 180px;" rowspan="1" colspan="1">
<bold>Baseline serum urate</bold>
</td>
                <td style="width: 186px;" rowspan="1" colspan="1">
<bold>Incidence of gout at 3 years</bold>
</td>
                <td style="width: 185px;" rowspan="1" colspan="1">
<bold>Incidence of gout at 5 years</bold>
</td>
                <td style="width: 196px;" rowspan="1" colspan="1">
<bold>Incidence of gout at 10 years</bold>
</td>
                <td style="width: 199.531px;" rowspan="1" colspan="1">
<bold>Incidence of gout at 15 years</bold>
</td>
              </tr>
              <tr>
                <td style="width: 180px;" rowspan="1" colspan="1">&#x0003c;6.0</td>
                <td style="width: 186px;" rowspan="1" colspan="1">0.21%</td>
                <td style="width: 185px;" rowspan="1" colspan="1">0.33%</td>
                <td style="width: 196px;" rowspan="1" colspan="1">0.79%</td>
                <td style="width: 199.531px;" rowspan="1" colspan="1">1.12%</td>
              </tr>
              <tr>
                <td style="width: 180px;" rowspan="1" colspan="1">6.0 to 6.9</td>
                <td style="width: 186px;" rowspan="1" colspan="1">0.37%</td>
                <td style="width: 185px;" rowspan="1" colspan="1">0.66%</td>
                <td style="width: 196px;" rowspan="1" colspan="1">1.98%</td>
                <td style="width: 199.531px;" rowspan="1" colspan="1">3.70%</td>
              </tr>
              <tr>
                <td style="width: 180px;" rowspan="1" colspan="1">7.0 to 7.9</td>
                <td style="width: 186px;" rowspan="1" colspan="1">0.92%</td>
                <td style="width: 185px;" rowspan="1" colspan="1">1.91%</td>
                <td style="width: 196px;" rowspan="1" colspan="1">6.37%</td>
                <td style="width: 199.531px;" rowspan="1" colspan="1">9.00%</td>
              </tr>
              <tr>
                <td style="width: 180px;" rowspan="1" colspan="1">8.0 to 8.9</td>
                <td style="width: 186px;" rowspan="1" colspan="1">4.00%</td>
                <td style="width: 185px;" rowspan="1" colspan="1">6.94%</td>
                <td style="width: 196px;" rowspan="1" colspan="1">11.32%</td>
                <td style="width: 199.531px;" rowspan="1" colspan="1">16.28%</td>
              </tr>
              <tr>
                <td style="width: 180px;" rowspan="1" colspan="1">9.0 to 9.9</td>
                <td style="width: 186px;" rowspan="1" colspan="1">8.31%</td>
                <td style="width: 185px;" rowspan="1" colspan="1">14.02%</td>
                <td style="width: 196px;" rowspan="1" colspan="1">24.18%</td>
                <td style="width: 199.531px;" rowspan="1" colspan="1">35.21%</td>
              </tr>
              <tr>
                <td style="width: 180px;" rowspan="1" colspan="1">10.0 or greater</td>
                <td style="width: 186px;" rowspan="1" colspan="1">10.00%</td>
                <td style="width: 185px;" rowspan="1" colspan="1">26.25%</td>
                <td style="width: 196px;" rowspan="1" colspan="1">40.00%</td>
                <td style="width: 199.531px;" rowspan="1" colspan="1">48.47%</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Hyperuricemia, while a significant risk factor, does not singularly account for the development of gout (see <bold>Table.&#x000a0;</bold>Risk Factors of Hyperuricemia and Gout); only a minority of&#x000a0;individuals with elevated uric acid levels actually develop the condition. To assess the impact of diet on uric acid levels, examining the lower physiological uric acid range in species that do not produce uricase becomes essential. Dietary sources that can contribute to hyperuricemia and gout include the consumption of animal food such as seafood (eg, shrimp and lobster), organs (eg, liver and kidney), and red meat (eg, pork and beef). Additionally, beverages&#x000a0;like alcohol, sweetened beverages, sodas, and those containing high-fructose corn syrup may also contribute to&#x000a0;the onset of this disease.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref><xref ref-type="bibr" rid="article-22376.r14">[14]</xref><xref ref-type="bibr" rid="article-22376.r15">[15]</xref></p>
        <p>Epidemiological studies&#x000a0;have reported a rising burden of gout, primarily&#x000a0;attributed to&#x000a0;lifestyle changes like increased protein consumption and a sedentary lifestyle. These shifts in habits underscore the intricate relationship between modern living patterns and the prevalence of gout in contemporary society.</p>
        <p>Additional&#x000a0;factors&#x000a0;linked&#x000a0;to gout and hyperuricemia include older age, male sex, obesity, a purine-rich diet, alcohol, certain medications, comorbid diseases, and genetic predisposition (see <bold>Table.&#x000a0;</bold>Causes of Hyperuricemia). Medications such as diuretics, low-dose aspirin, ethambutol, pyrazinamide, and cyclosporine have been identified as potential contributors to elevated uric acid levels and gout development.&#x000a0;&#x000a0;</p>
        <table-wrap id="article-22376.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3. Risk Factors of Hyperuricemia and Gout&#x000a0;[1][8][16]</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; <bold>&#x000a0;Modifiable risk factors</bold></td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; <bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Nonmodifiable risk factors &#x000a0; &#x000a0;</bold> &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">Hypertension</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">Age</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">Obesity</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">Genetic variants</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">Hyperlipidemia</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">Gender</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">Diabetes mellitus</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">Ethnicity</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">Cardiovascular disease</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Alcohol</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Medications altering urate balance</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Chronic kidney disease</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 342px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Dietary factors</td>
                <td style="width: 487.263px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="article-22376.table3" position="float" orientation="portrait">
          <caption>
            <title>Table 4. Causes of Hyperuricemia</title>
          </caption>
          <table style="height: 594px; width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 40px;">
                <td style="width: 205px; height: 40px;" rowspan="1" colspan="1">
<bold>Clinical disorders leading to urate and/or purine overproduction</bold>
</td>
                <td style="width: 253px; height: 40px;" rowspan="1" colspan="1">
<bold>Drug, diet, or toxin-induced urate and/or purine overproduction</bold>
</td>
                <td style="width: 287.325px; height: 40px;" rowspan="1" colspan="1">
<bold>Inherited enzyme defects leading to purine overproduction (rare monogenic disorders)</bold>
</td>
                <td style="width: 276.675px; height: 40px;" rowspan="1" colspan="1">
<p><bold>Causes of hyperuricemia due to decreased uric acid clearance</bold></p>
</td>
              </tr>
              <tr style="height: 27px;">
                <td style="width: 205px; height: 27px;" rowspan="1" colspan="1">Malignancies</td>
                <td style="width: 253px; height: 27px;" rowspan="1" colspan="1">Cytotoxic drugs</td>
                <td style="width: 287.325px; height: 27px;" rowspan="1" colspan="1">Glucose-6-phosphatase deficiency (glycogen storage disease, type I)</td>
                <td style="width: 276.675px; height: 27px;" rowspan="1" colspan="1">Diabetic or starvation ketoacidosis</td>
              </tr>
              <tr style="height: 27px;">
                <td style="width: 205px; height: 27px;" rowspan="1" colspan="1">Hemolytic disorders</td>
                <td style="width: 253px; height: 27px;" rowspan="1" colspan="1">Ethanol</td>
                <td style="width: 287.325px; height: 27px;" rowspan="1" colspan="1">Hypoxanthine-guanine phosphoribosyltransferase deficiency</td>
                <td style="width: 276.675px; height: 27px;" rowspan="1" colspan="1">Lactic acidosis</td>
              </tr>
              <tr style="height: 27px;">
                <td style="width: 205px; height: 27px;" rowspan="1" colspan="1">Myeloproliferative disorders</td>
                <td style="width: 253px; height: 27px;" rowspan="1" colspan="1">
<p>Fructose&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; (high fructose corn syrup)</p>
</td>
                <td style="width: 287.325px; height: 27px;" rowspan="1" colspan="1">Phosphoribosylpyrophosphate synthetase overactivity</td>
                <td style="width: 276.675px; height: 27px;" rowspan="1" colspan="1">Chronic renal insufficiency of any form</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 205px; height: 13px;" rowspan="1" colspan="1">Lymphoproliferative disorders</td>
                <td style="width: 253px; height: 13px;" rowspan="1" colspan="1">Ethylamino-1,3,4-thiadiazole</td>
                <td style="width: 287.325px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 276.675px; height: 13px;" rowspan="1" colspan="1">Lead nephropathy (saturnine gout)</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 205px; height: 13px;" rowspan="1" colspan="1">Tissue hypoxia</td>
                <td style="width: 253px; height: 13px;" rowspan="1" colspan="1">Vitamin B12 deficiency</td>
                <td style="width: 287.325px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 276.675px; height: 13px;" rowspan="1" colspan="1">Hyperparathyroidism</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 205px; height: 13px;" rowspan="1" colspan="1">Down syndrome</td>
                <td style="width: 253px; height: 13px;" rowspan="1" colspan="1">Pancreatic extract</td>
                <td style="width: 287.325px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 276.675px; height: 13px;" rowspan="1" colspan="1">Sarcoidosis</td>
              </tr>
              <tr style="height: 27.8px;">
                <td style="width: 205px; height: 27.8px;" rowspan="1" colspan="1">Psoriasis</td>
                <td style="width: 253px; height: 27.8px;" rowspan="1" colspan="1">Excessive dietary purine ingestion</td>
                <td style="width: 287.325px; height: 27.8px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 276.675px; height: 27.8px;" rowspan="1" colspan="1">Chronic beryllium disease</td>
              </tr>
              <tr style="height: 27.8px;">
                <td style="width: 205px; height: 27.8px;" rowspan="1" colspan="1">Glycogen storage diseases (types III, V, VII)</td>
                <td style="width: 253px; height: 27.8px;" rowspan="1" colspan="1">4-amino-5-imidazole carboxamide riboside</td>
                <td style="width: 287.325px; height: 27.8px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 276.675px; height: 27.8px;" rowspan="1" colspan="1">Hypothyroidism</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 205px; height: 13px;" rowspan="1" colspan="1">Obesity</td>
                <td style="width: 253px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 287.325px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 276.675px; height: 13px;" rowspan="1" colspan="1">Preeclampsia</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 205px; height: 13px;" rowspan="1" colspan="1">Insulin Resistance syndrome</td>
                <td style="width: 253px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 287.325px; height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 276.675px; height: 13px;" rowspan="1" colspan="1">Effective volume depletion (eg, fluid losses and heart failure)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Triggers</bold>
</p>
        <p>Any&#x000a0;condition&#x000a0;leading to changes in extracellular urate concentration has the potential to trigger a gout flare-up.&#x000a0;These conditions include various factors such as stress (mainly due to medical illnesses like cardiovascular illnesses, recent surgical procedure, trauma, dehydration, or starvation), dietary&#x000a0;choices (such as the consumption of&#x000a0;high-purine foods like organ meats or seafood, as well as alcoholic beverages like beer, wine, and spirits), and drugs (including aspirin, diuretics, or even allopurinol).</p>
        <p>
<bold>Dietary Factors That May Lower Serum Uric Acid</bold>
</p>
        <p>Certain dietary practices have been shown to lower serum uric and reduce the risk of incident gout. Higher consumption of meat and seafood is associated with an increased incidence of gout in men. Conversely, increased intake of dairy&#x000a0;products is associated with decreased incident gout in men.<xref ref-type="bibr" rid="article-22376.r17">[17]</xref>&#x000a0;Additionally, following the Dietary Approaches to Stop Hypertension (DASH) diet has been&#x000a0;proven to decrease serum uric acid levels&#x000a0;and mitigate the risk of gout.<xref ref-type="bibr" rid="article-22376.r18">[18]</xref><xref ref-type="bibr" rid="article-22376.r19">[19]</xref>&#x000a0;Adequate vitamin C intake&#x000a0;is associated&#x000a0;with&#x000a0;decreased serum uric acid and a reduced risk of gout.<xref ref-type="bibr" rid="article-22376.r20">[20]</xref><xref ref-type="bibr" rid="article-22376.r21">[21]</xref><xref ref-type="bibr" rid="article-22376.r22">[22]</xref><xref ref-type="bibr" rid="article-22376.r23">[23]</xref><xref ref-type="bibr" rid="article-22376.r24">[24]</xref>&#x000a0;Furthermore, incorporating cherries&#x000a0;into the diet has&#x000a0;demonstrated&#x000a0;a decrease in serum uric acid<xref ref-type="bibr" rid="article-22376.r25">[25]</xref>&#x000a0;and a reduced&#x000a0;risk of recurrent&#x000a0;gout attacks.<xref ref-type="bibr" rid="article-22376.r18">[18]</xref><xref ref-type="bibr" rid="article-22376.r26">[26]</xref></p>
      </sec>
      <sec id="article-22376.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Epidemiological estimates depend on the disease definition. A definitive diagnosis of gout is accepted in the presence of monosodium urate monohydrate crystals in the joint fluid or the&#x000a0;identification of tophus. However, given the impracticality of identifying gout through these criteria alone, various case definitions have been&#x000a0;devised like self-reports, Rome criteria, the New York criteria, the American College of Rheumatology (ACR) criteria, and the 2015 ACR/European League Against Rheumatism (EULAR) criteria. The 2015 ACR/EULAR criteria have a sensitivity of 92% and specificity of 89%, surpassing the accuracy of all previous definitions and ensuring a more precise and reliable diagnosis of gout in epidemiological studies.&#x000a0;</p>
        <p>In men, serum urate levels&#x000a0;typically range from&#x000a0;5 to 6 mg/dL and are usually&#x000a0;attained during puberty, with a slight increase in levels due to age alone.<xref ref-type="bibr" rid="article-22376.r27">[27]</xref>&#x000a0;Conversely, women exhibit lower serum urate&#x000a0;concentrations&#x000a0;averaging 1.0&#x000a0;to 1.5 mg/dL, less than men of corresponding ages,<xref ref-type="bibr" rid="article-22376.r28">[28]</xref><xref ref-type="bibr" rid="article-22376.r29">[29]</xref>&#x000a0;a difference likely influenced by renal uric acid clearance under the influence of estrogen. Following menopause, urate concentrations in women rise to levels comparable to those in adult men.<xref ref-type="bibr" rid="article-22376.r30">[30]</xref>&#x000a0;The gender-based variation in urate concentration affects the clinical differences between women and men at the onset of gout.<xref ref-type="bibr" rid="article-22376.r31">[31]</xref><xref ref-type="bibr" rid="article-22376.r32">[32]</xref></p>
        <p>The prevalence of gout can vary by age, sex, and country of origin. Generally,&#x000a0;the prevalence of gout is 1% to 4%. Older age and male sex are&#x000a0;2 common risk factors recognized globally. In Western nations, the prevalence of gout&#x000a0;is significantly higher in men (3%-6%) compared to women (1%-2%), with a notable 2- to 6-fold&#x000a0;difference. The prevalence of gout&#x000a0;rises with age but plateaus after 70 years (see <bold>Table.&#x000a0;</bold>Prevalence by Age Range).</p>
        <p>Data from 2007 to 2008 revealed that around 3.9% of US adults received a gout diagnosis.<xref ref-type="bibr" rid="article-22376.r33">[33]</xref>&#x000a0;Estimates regarding gout prevalence in the United States range from less than&#x000a0;3 million&#x000a0;to over 8 million individuals. The&#x000a0;latest estimates suggest a gout prevalence of over&#x000a0;3%&#x000a0;among the adult American population.<xref ref-type="bibr" rid="article-22376.r34">[34]</xref><xref ref-type="bibr" rid="article-22376.r35">[35]</xref><xref ref-type="bibr" rid="article-22376.r36">[36]</xref>&#x000a0;</p>
        <p>Additionally, data&#x000a0;based on the National Health and Nutrition Examination Survey (NHANES)&#x000a0; from 2007 to 2016 indicate a higher prevalence of gout in African-American individuals than in White&#x000a0;individuals&#x000a0;in the USA. Among females, gout prevalence is 3.5% in African Americans and 2.0% in White&#x000a0;Americans, with an odds ratio (OR) of&#x000a0;1.81. Among males, the prevalence in African Americans is 7.0% and 5.4% in&#x000a0;White&#x000a0;Americans,&#x000a0;with an OR of 1.26. Hyperuricemia was also more prevalent in African American females and males than&#x000a0;their White counterparts, with OR of 2.00 and 1.39, respectively.<xref ref-type="bibr" rid="article-22376.r37">[37]</xref>&#x000a0;&#x000a0;</p>
        <table-wrap id="article-22376.table4" position="float" orientation="portrait">
          <caption>
            <title>Table 5.&#x000a0;Prevalence by Age Range&#x000a0;</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 115px; height: 13px;" rowspan="1" colspan="1">Location/Age (years)</td>
                <td style="width: 72px; height: 13px;" rowspan="1" colspan="1">
<p>20-29</p>
</td>
                <td style="width: 79px; height: 13px;" rowspan="1" colspan="1">&#x000a0;30-39</td>
                <td style="width: 79.4062px; height: 13px;" rowspan="1" colspan="1">40-49</td>
                <td style="width: 79.5938px; height: 13px;" rowspan="1" colspan="1">50-59</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">60-69</td>
                <td style="width: 68px; height: 13px;" rowspan="1" colspan="1">70-79</td>
                <td style="width: 71px; height: 13px;" rowspan="1" colspan="1">80-85</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x0003e;85</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 115px; height: 13px;" rowspan="1" colspan="1">USA</td>
                <td style="width: 72px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 0.70</td>
                <td style="width: 79px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0;0.70</td>
                <td style="width: 79.4062px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 3.40</td>
                <td style="width: 79.5938px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 3.40</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 8.80</td>
                <td style="width: 68px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;8.80</td>
                <td style="width: 71px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;8.70</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 8.70</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 115px; height: 13px;" rowspan="1" colspan="1">Australia</td>
                <td style="width: 72px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;0.08</td>
                <td style="width: 79px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0;0.33</td>
                <td style="width: 79.4062px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 1.84</td>
                <td style="width: 79.5938px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 1.68</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 3.03</td>
                <td style="width: 68px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;4.9</td>
                <td style="width: 71px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;6.72</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;7.19</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 115px; height: 13px;" rowspan="1" colspan="1">Sweden</td>
                <td style="width: 72px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;0.06</td>
                <td style="width: 79px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0;0.27</td>
                <td style="width: 79.4062px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 0.80</td>
                <td style="width: 79.5938px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 1.54</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 2.83</td>
                <td style="width: 68px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;4.89</td>
                <td style="width: 71px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;6.61</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;7.38</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 115px; height: 13px;" rowspan="1" colspan="1">South Korea</td>
                <td style="width: 72px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;0.03</td>
                <td style="width: 79px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0;0.20</td>
                <td style="width: 79.4062px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 0.59</td>
                <td style="width: 79.5938px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 0.85</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; 1.15</td>
                <td style="width: 68px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;1.59</td>
                <td style="width: 71px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;1.90</td>
                <td style="width: 77px; height: 13px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0;1.49</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The incidence rates of gout have&#x000a0;displayed&#x000a0;an&#x000a0;upward trend over the past several decades, with a higher incidence&#x000a0;observed in men than women and the incidence&#x000a0;rising with age. A study conducted in Olmsted County, MN, from 1989 to 2009 revealed increased gout incidence and comorbidities over the 20 years.<xref ref-type="bibr" rid="article-22376.r38">[38]</xref>&#x000a0;Similarly, in the United Kingdom, the prevalence of gout experienced an escalation from 1.52% to 2.49% between 1997 and 2012.<xref ref-type="bibr" rid="article-22376.r39">[39]</xref></p>
        <p>
<bold>Comorbidities</bold>
</p>
        <p>Gout is associated with&#x000a0;health risks, including&#x000a0;obesity, hypertension (HTN), chronic kidney disease (CKD), diabetes mellitus (DM), hyperlipidemia (HLD), and metabolic syndrome. A study&#x000a0;conducted in&#x000a0;Olmsted County, MN,&#x000a0;highlighted the increased prevalence of various&#x000a0;comorbidities in gout patients compared to the general population. The prevalence of obesity (defined as BMI &#x0003e;35 kg/m2) was 29% in gout patients&#x000a0;versus 10% in the general population, HTN was 69%&#x000a0;versus 54%, CKD was 28% versus 11%, DM was 25%&#x000a0;versus 6%,&#x000a0;HLD was 61%&#x000a0;versus 21%.<xref ref-type="bibr" rid="article-22376.r38">[38]</xref>&#x000a0;</p>
        <p>Gaining weight&#x000a0;during adulthood&#x000a0;has been consistently&#x000a0;associated with a heightened risk&#x000a0;of developing gout.<xref ref-type="bibr" rid="article-22376.r40">[40]</xref><xref ref-type="bibr" rid="article-22376.r41">[41]</xref><xref ref-type="bibr" rid="article-22376.r42">[42]</xref>&#x000a0;Studies from the United Kingdom and Germany have revealed associations between gout and&#x000a0;various comorbidities, including DM, congestive heart failure (CHF), HTN, myocardial infarction (MI), and obesity. Additionally, the prevalence of comorbidities increased with higher serum uric acid levels.<xref ref-type="bibr" rid="article-22376.r43">[43]</xref>&#x000a0;</p>
        <p>Other gout-related comorbidities include HLD, hypothyroidism, anemia, psoriasis, chronic pulmonary disease, osteoarthritis, and depression.<xref ref-type="bibr" rid="article-22376.r44">[44]</xref>&#x000a0;Due to increased cell turnover in the epidermis, psoriasis leads to elevated uric acid production. At the same time, patients with&#x000a0;CKD&#x000a0;experience&#x000a0;reduced urate excretion, resulting&#x000a0;in hyperuricemia and an increased risk of incident gout.<xref ref-type="bibr" rid="article-22376.r45">[45]</xref>&#x000a0;</p>
        <p>Gout is associated with a heightened risk of ischemic heart disease (hazard ratio [HR] 1.86), MI (HR 3.246), and cerebrovascular disease (HR 1.552).<xref ref-type="bibr" rid="article-22376.r46">[46]</xref>&#x000a0;Moreover, individuals&#x000a0;with recent gout flares experience a transient increase in cardiovascular events.<xref ref-type="bibr" rid="article-22376.r47">[47]</xref></p>
        <p>Gout is&#x000a0;linked to&#x000a0;increased overall mortality, encompassing all-cause mortality and specific causes such as cardiovascular disease, infectious disease, and cancer-related deaths.<xref ref-type="bibr" rid="article-22376.r48">[48]</xref>&#x000a0;Particularly, gout is strongly associated with elevated&#x000a0;cardiovascular mortality&#x000a0;<xref ref-type="bibr" rid="article-22376.r49">[49]</xref>&#x000a0;and contributes to mortality related to&#x000a0;renal disease, digestive diseases, and dementia.<xref ref-type="bibr" rid="article-22376.r50">[50]</xref></p>
        <p>The&#x000a0;connection between&#x000a0;gout&#x000a0;and dementia, including Parkinson disease, is&#x000a0;complex and not fully understood. Studies have shown&#x000a0;varied&#x000a0;associations, with some indicating a lower risk of dementia,<xref ref-type="bibr" rid="article-22376.r51">[51]</xref><xref ref-type="bibr" rid="article-22376.r52">[52]</xref><xref ref-type="bibr" rid="article-22376.r53">[53]</xref>&#x000a0;specifically Alzheimer disease,<xref ref-type="bibr" rid="article-22376.r54">[54]</xref><xref ref-type="bibr" rid="article-22376.r55">[55]</xref>&#x000a0;in individuals with hyperuricemia and gout. However, conflicting data suggests that hyperuricemia and gout are associated with an increased risk of dementia.<xref ref-type="bibr" rid="article-22376.r56">[56]</xref><xref ref-type="bibr" rid="article-22376.r57">[57]</xref>&#x000a0;Similarly, the relationship between gout and&#x000a0;Parkinson disease is inconclusive, with studies showing differing results, including lower,<xref ref-type="bibr" rid="article-22376.r58">[58]</xref><xref ref-type="bibr" rid="article-22376.r59">[59]</xref><xref ref-type="bibr" rid="article-22376.r60">[60]</xref>&#x000a0;no specific,<xref ref-type="bibr" rid="article-22376.r61">[61]</xref><xref ref-type="bibr" rid="article-22376.r62">[62]</xref>&#x000a0;or a higher risk of Parkinson disease&#x000a0;in patients with gout.<xref ref-type="bibr" rid="article-22376.r63">[63]</xref></p>
      </sec>
      <sec id="article-22376.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Gout is an inflammatory arthritis triggered by the deposition of MSU crystals, the end product of human purine metabolism, in joints, soft tissues, and bones.&#x000a0;This condition may manifest in many forms, including acute gout flare (acute arthritis), chronic gouty arthritis (chronic arthritis), tophaceous gout (formation of tophi), renal functional impairment, and urolithiasis.<xref ref-type="bibr" rid="article-22376.r64">[64]</xref><xref ref-type="bibr" rid="article-22376.r65">[65]</xref><xref ref-type="bibr" rid="article-22376.r66">[66]</xref>&#x000a0;</p>
        <p>The&#x000a0;pathophysiology of gout involves a series of complex and interacting processes as follows:<xref ref-type="bibr" rid="article-22376.r67">[67]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Various genetic and metabolic factors&#x000a0;contribute to hyperuricemia in the bloodstream.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic, physiologic, and other characteristics are responsible for MSU crystal formation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Soluble inflammatory factors, cellular elements, innate immune processes, along with the characteristics of MSU crystals, promote&#x000a0;an acute inflammatory response.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immune mechanisms&#x000a0;come into play to&#x000a0;mediate the resolution of acute inflammation induced by MSU crystals.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic inflammatory processes&#x000a0;coupled with the effects of immune cells and crystals on osteoblasts, chondrocytes, and osteoclasts contribute to cartilage attrition, bone erosion, joint injury, and the formation of tophi.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Uric Acid Physiology</bold>
</p>
        <p>Uric acid is the final product of purine metabolism in humans and higher primate species due to a mutation that silences&#x000a0;the gene decoding the enzyme uricase.<xref ref-type="bibr" rid="article-22376.r8">[8]</xref><xref ref-type="bibr" rid="article-22376.r9">[9]</xref>&#x000a0;Traditionally, it was believed that uric acid&#x000a0;played a crucial role as a natural antioxidant in the human body, primarily responsible for eliminating reactive oxygen species. However, recent studies revealed&#x000a0;that&#x000a0;uric acid is not a significant factor in controlling oxidative stress. Instead, it is thought to be involved in immune surveillance and&#x000a0;regulating blood pressure and intravascular volume.</p>
        <p>Uric acid is a weak organic acid that predominantly exists in its ionized form, MSU, at pH 7.4. This form is less soluble due to the high sodium concentration. In acidic environments like urine, uric acid exists in&#x000a0;its nonionized form, which is even less soluble within the physiological range. Consequently, uric acid crystals and stones can form in the urinary tract, distinguishing them&#x000a0;from MSU associated with gout.<xref ref-type="bibr" rid="article-22376.r8">[8]</xref></p>
        <p>Most urate in the body is&#x000a0;produced endogenously in the liver with a&#x000a0;minor contribution from the small intestines.&#x000a0;Renal excretion is pivotal in managing the body's urate pool under steady-state conditions since the&#x000a0;glomerulus filters nearly all urate. In a hyperuricemic state, the urate pool expands.</p>
        <p>In men, the normal urate range is 800 to 1000 mg; in women, it ranges from 500 to 1000 mg. Urate turnover ranges from 500 to 1000 mg daily. During male puberty, serum urate concentrations&#x000a0;increase to reach the adult range, whereas urate levels remain low in&#x000a0;females of reproductive age.&#x000a0;This disparity is due to&#x000a0;estrogen's impact on renal urate transporters, resulting in less renal urate reabsorption and increased clearance in women. However, in menopausal and postmenopausal women, urate levels approach those of adult males and may be&#x000a0;influenced by hormone replacement therapies.<xref ref-type="bibr" rid="article-22376.r8">[8]</xref></p>
        <p>The following distinguishes between causes of lower and higher urate levels:</p>
        <p>
<bold>Lowered urate pool&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Raised urate pool</bold>
</p>
        <table-wrap id="article-22376.table5" position="float" orientation="portrait">
          <table style="width: 448.25px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 189px;" rowspan="1" colspan="1">Intestinal excretion (ABCG2)</td>
                <td style="width: 191.25px;" rowspan="1" colspan="1">Renal tubular reabsorption</td>
              </tr>
              <tr>
                <td style="width: 189px;" rowspan="1" colspan="1">Glomerular filtration</td>
                <td style="width: 191.25px;" rowspan="1" colspan="1">Dietary purines, alcohol</td>
              </tr>
              <tr>
                <td style="width: 189px;" rowspan="1" colspan="1">Urate-lowering drugs</td>
                <td style="width: 191.25px;" rowspan="1" colspan="1">Metabolic disorders, insulin resistance</td>
              </tr>
              <tr>
                <td style="width: 189px;" rowspan="1" colspan="1">Weight reduction</td>
                <td style="width: 191.25px;" rowspan="1" colspan="1">Purine salvage pathways</td>
              </tr>
              <tr>
                <td style="width: 189px;" rowspan="1" colspan="1">Renal tubular secretion</td>
                <td style="width: 191.25px;" rowspan="1" colspan="1">ATP turnover</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Hyperuricemia</bold>
</p>
        <p>Hyperuricemia plays a&#x000a0;pivotal role&#x000a0;in developing gout as it facilitates the nucleation and growth of&#x000a0;MSU crystals by reducing urate solubility. Several factors promote hyperuricemia in humans, like the genetic absence of uricase, the reabsorption of 90% of filtered uric acid, and the limited solubility of MSU and urate in body fluids.&#x000a0;An imbalance in the production and excretion&#x000a0;of uric acid leads to rising serum uric acid levels.<xref ref-type="bibr" rid="article-22376.r10">[10]</xref>&#x000a0;When renal urate excretion is decreased, intestinal uricolysis increases to half of the total urate disposal, with&#x000a0;the transporter ABCG2&#x000a0;playing a pivotal role.&#x000a0;Serum urate concentrations exceeding 6.8 mg/dL become&#x000a0;saturated&#x000a0;and increase the risk of crystal deposition. Hyperuricemia affects 20% of adult white men in the US and is associated with several chronic disorders.&#x000a0;</p>
        <p>Hyperuricemia can occur as either primary (idiopathic) or secondary. Overproduction of uric acid is observed in several diseases, toxic states, and due to certain medications. Examples include acute leukemia, tumor lysis syndrome, and psoriasis.</p>
        <p>
<bold>Purine Metabolism</bold>
</p>
        <p>Purines&#x000a0;consist of&#x000a0;9-carbon purine nuclei&#x000a0;that form fused pyrimidine and imidazole rings. Purines&#x000a0;perform essential functions in all living cells through purine-based nucleic acids, including adenine, guanine, and hypoxanthine. The contribution of dietary purines to the urate pool is significant.&#x000a0;Removing purines&#x000a0;from the diet of normal individuals for 10 days reduces urate levels by 25% and urinary uric acid excretion by 50%. However, implementing severely purine-restricted diets&#x000a0;is impractical. Conversely, diets high in fructose, meat, alcohol, and fish promote hyperuricemia.<xref ref-type="bibr" rid="article-22376.r17">[17]</xref></p>
        <p>The endogenous pathway of purine production, known as de novo purine synthesis, involves the conversion of ribose-5-phosphate from 5-phosphoribosyl 1-pyrophosphate (PRPP) into nucleotide inosine monophosphate through 10 key steps. This energy-intensive process prompts energy conservation through the interconversion and salvage of purine nucleotides. Urate precursors of purine degradation are hypoxanthine and guanine, most of which are salvaged. Unused guanine is deaminated to become xanthine, while hypoxanthine is oxidized to xanthine by xanthine oxidase.<xref ref-type="bibr" rid="article-22376.r8">[8]</xref></p>
        <p>Xanthine oxidase is a flavoprotein containing molybdenum-pterin and iron sulfide clusters. It operates in 2 forms: as&#x000a0;an oxidase, utilizing oxygen to convert hypoxanthine to xanthine and&#x000a0;then to urate, and&#x000a0;as a dehydrogenase, using nicotinamide adenine dinucleotide (NAD+). Inhibiting xanthine oxidase is the primary target&#x000a0;for lowering urate levels in patients with gout.</p>
        <p>The primary regulatory steps in purine synthesis include:</p>
        <list list-type="order">
          <list-item>
            <p>The synthesis of PRPP in the&#x000a0;PRPP synthetase pathway.</p>
          </list-item>
          <list-item>
            <p>The utilization of PRPP in the first step of de novo purine synthesis.</p>
          </list-item>
        </list>
        <p>The pathway is regulated through inhibition by purine nucleotide products of purine synthesis and&#x000a0;activation by increased PRPP. This antagonistic control mechanism is disrupted in&#x000a0;2 rare X-linked disorders: deficiency of the salvage enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT) and overactivity of PRPP synthetase (PRS1). Conditions such as excessive adenosine triphosphate (ATP) depletion&#x000a0;during tissue hypoxia or acute alcohol intoxication&#x000a0;can lead to decreased concentrations of inhibitory nucleotides and excess urate production.</p>
        <p>
<bold>Renal Uric Acid Secretion</bold>
</p>
        <p>In adults, only 5% to 10% of uric acid&#x000a0;is cleared compared to creatinine clearance, despite 100% uric acid filtration at the glomerulus. This is because 90% of the filtered uric acid is reabsorbed in the renal tubules.&#x000a0;Consequently, individuals with hyperuricemia&#x000a0;resulting from impaired renal excretion&#x000a0;may exhibit normal urinary urate levels due to impaired uric acid clearance. Through genomic and molecular studies, researchers have identified several renal uric acid clearance transporters. Among these, glucose transporter 9 (GLUT9) and urate anion transoporter 1 (URAT1) strongly affect&#x000a0;serum urate levels.<xref ref-type="bibr" rid="article-22376.r6">[6]</xref><xref ref-type="bibr" rid="article-22376.r66">[66]</xref></p>
        <p>
<bold>Glucose Transporter 9 (GLUT9)</bold>
</p>
        <p>GLUT9, a product of the SLC2A9 genel, functions as a voltage-driven urate transporter responsible for&#x000a0;mediating uric acid reabsorption from tubular cells. GLUT9 exists in 2 isoforms: GLUT9L, located on the basolateral side of the proximal renal tubular epithelium, and GLUT9S, located on the apical side.&#x000a0;This transporter is&#x000a0;also expressed in the hepatocytes and regulates serum urate concentrations&#x000a0;through its dual effects in the kidney and the liver. Additionally, GLUT9&#x000a0;facilitates the transfer of&#x000a0;glucose and fructose, which&#x000a0;could explain the dietary influence of these substances on hyperuricemia.&#x000a0;Studies involving mice with a GLUT9 knockout had moderate hyperuricemia, massive hyperuricosuria, and early-onset nephropathy.<xref ref-type="bibr" rid="article-22376.r6">[6]</xref></p>
        <p>
<bold>URAT1</bold>
</p>
        <p>URAT1, encoded by the SLC22A12 gene, is highly specific for uric acid and influences&#x000a0;renal uric acid transport by mediating the exchange of various anions. Mutations in SLC22A12 can lead to hypouricemia, hyperuricosuria, and exercise-induced renal functional impairment. Uricosuric drugs like probenecid, benzbromarone, and lesinurad inhibit URAT1 and increase uric acid excretion. Other urate transporters include ABCG2, NPT1, NPT4, and multidrug resistance protein 4 (MRP4).<xref ref-type="bibr" rid="article-22376.r6">[6]</xref></p>
        <p>
<bold>Autosomal Dominant Tubulointerstitial Kidney Disease </bold>
</p>
        <p>Tubulointerstitial kidney disease, caused&#x000a0;by pathogenic variants in the UMOD&#x000a0;gene,&#x000a0;is characterized by early-onset hyperuricemia (with or without gout), hypertension, and progressive tubulointerstitial inflammation and fibrosis. This condition leads&#x000a0;to end-stage renal disease by the age of 40. Previously&#x000a0;known as familial juvenile hyperuricemia nephropathy and medullary cystic kidney disease, most affected patients&#x000a0;exhibit&#x000a0;a mutation in uromodulin, which encodes the Tamm-Horsfall protein. Uromodulin maintains the integrity of the ascending loop of Henle by forming a gel-like lattice that coats the luminal side of the tubule. Defects in the lattice alter solute fluxes, reducing Na and Cl reabsorption, decreasing extracellular volume, and compensatory enhancement of sodium-dependent urate transport in the proximal tubule.&#x000a0;</p>
        <p>
<bold>Extrarenal Urate Excretion</bold>
</p>
        <p>In the intestines, urate excretion is facilitated by the ABCG2 transporter. Studies involving reduced ABCG2 knockout mice revealed that reduced intestinal urate excretion increased serum urate levels. Consequently, hyperuricemia resulting from urate overproduction can be classified as a renal overload type consisting of extrarenal underexcretion and genuine urate overproduction subtypes.&#x000a0;</p>
        <p>
<bold>Urate Crystal Formation</bold>
</p>
        <p>The formation of MSU crystals requires sustained supersaturated concentrations of urate. Factors like the presence of particulate seed, local cation concentrations, pH, temperature, and dehydration influence crystal formation (see <bold>Table.&#x000a0;</bold>Factors Influencing Urate&#x000a0;Crystal Formation).<xref ref-type="bibr" rid="article-22376.r66">[66]</xref><xref ref-type="bibr" rid="article-22376.r68">[68]</xref><xref ref-type="bibr" rid="article-22376.r69">[69]</xref><xref ref-type="bibr" rid="article-22376.r70">[70]</xref>&#x000a0;Immunoglobulin (Ig) G may also facilitate crystal formation and growth in patients with gout. MSU crystals tend to form in the first metatarsophalangeal joint, midfoot, and Achilles tendon. Emerging evidence indicates a&#x000a0;connection between osteoarthritis (OA) and sites of MSU crystal deposition.&#x000a0;In osteoarthritic joints, cartilage degradation products like chondroitin sulfate lowers urate solubility, promoting nucleation and crystal growth.<xref ref-type="bibr" rid="article-22376.r68">[68]</xref>&#x000a0;The solubility of MSU drops rapidly with decreasing temperature, further impacting crystal formation and deposition.<xref ref-type="bibr" rid="article-22376.r5">[5]</xref></p>
        <table-wrap id="article-22376.table6" position="float" orientation="portrait">
          <caption>
            <title>Table 6.&#x000a0;Factors Influencing Urate&#x000a0;Crystal Formation</title>
          </caption>
          <table style="width: 405.824px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 370.824px;" rowspan="1" colspan="1">Presence of particulate seed nuclei like cartilage debris, collagen, hyaluronate, chondroitin sulfate</td>
              </tr>
              <tr>
                <td style="width: 370.824px;" rowspan="1" colspan="1">Local cation concentrations</td>
              </tr>
              <tr>
                <td style="width: 370.824px;" rowspan="1" colspan="1">pH</td>
              </tr>
              <tr>
                <td style="width: 370.824px;" rowspan="1" colspan="1">Temperature</td>
              </tr>
              <tr>
                <td style="width: 370.824px;" rowspan="1" colspan="1">Dehydration</td>
              </tr>
              <tr>
                <td style="width: 370.824px;" rowspan="1" colspan="1">The balance between macromolecular inhibitors and promoters</td>
              </tr>
              <tr>
                <td style="width: 370.824px;" rowspan="1" colspan="1">IgM&#x000a0;and IgG</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Inflammatory Response</bold>
</p>
        <p>Histopathologic and imaging studies have shown the presence of urate crystals within joints for prolonged periods without causing overt inflammatory reactions. Heavily crystal-laden fluids (urate milk) are sometimes found in uninflamed joints and bursae. The dense urate crystal mass in tophi sometimes reaches massive dimensions with minor inflammation and symptoms until&#x000a0;they exert&#x000a0;critical compression of surrounding tissues.</p>
        <p>The initiation of inflammation in gout involves microcrystals usually shed from preexisting synovial tophi. This is supported by observing acute gout flares with rapid changes in urate concentrations. The initiation of inflammation depends on multiple factors like the crystal size, the proteins and molecules coating them, and the recruitment of inflammatory cells. MSU crystal surfaces can bind to&#x000a0;various proteins, including IgG, lipoproteins, and lipids (see <bold>Table.</bold> Inflammatory Events in Acute Gout Flare).<xref ref-type="bibr" rid="article-22376.r8">[8]</xref></p>
        <p>The IgG conformational changes encourage phagocytosis by cells&#x000a0;possessing Fc-y receptors, such as neutrophils and macrophages.<xref ref-type="bibr" rid="article-22376.r71">[71]</xref>&#x000a0;IgG also activates the classical complement pathway. MSU crystals can also directly activate the classical and alternative complement pathways,<xref ref-type="bibr" rid="article-22376.r72">[72]</xref><xref ref-type="bibr" rid="article-22376.r73">[73]</xref>&#x000a0;leading to opsonization by depositing the complement split product C3b on the crystals. The apolipoprotein coating on the MSU crystals counteracts the opsonic effects of the IgG Fc and complement proteins. Additionally, it inhibits neutrophil stimulation. Thus, the inflammatory potential of the MSU crystals is a balance between the proinflammatory and anti-inflammatory elements coating the crystal surface. In acute gout, neutrophils are the predominant inflammatory cells in the synovial tissue and fluid,&#x000a0;contributing&#x000a0;significantly to the proinflammatory stimulus.<xref ref-type="bibr" rid="article-22376.r8">[8]</xref></p>
        <p>In patients with asymptomatic tophi, synovial fluid macrophages&#x000a0;frequently contain MSU microcrystals,&#x000a0;suggesting active engagement with phagocytes without apparent inflammation. Synovial macrophages and blood monocytes mount a vigorous response to MSU crystals compared to well-differentiated macrophages due to the release of TGF-b1.&#x000a0;Researchers have studied 2&#x000a0;main mechanisms of MSU crystal interaction with phagocytes.</p>
        <list list-type="order">
          <list-item>
            <p>Activation of phagocytes&#x000a0;leads to lysosomal fusion, respiratory burst, and the release of lysosomal enzymes and inflammatory mediators, including TNF-alpha and IL-8.<xref ref-type="bibr" rid="article-22376.r67">[67]</xref></p>
          </list-item>
          <list-item>
            <p>The predominant pathway of cytosolic protein complex&#x000a0;activation&#x000a0;involves&#x000a0;the&#x000a0;NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome. MSU crystals activate macrophages and monocytes via toll-like receptors (TLR) 2 and 4, resulting in signal transduction by My88, interleukin-1 receptor-associated kinase 1 (IRAK1), and IRAK4. This activation&#x000a0;triggers nuclear factor-kB, which activates the NLRP3 inflammasome. The&#x000a0;activated NLRP3 inflammasome subsequently recruits caspase-1, which&#x000a0;processes&#x000a0;pro-interleukin-1&#x003b2; (IL-1&#x003b2;) into its active form,&#x000a0;IL-1&#x003b2;. IL-1&#x003b2; plays an important role in the inflammatory response to gout by promoting vasodilatation, recruiting monocytes, and&#x000a0;initiating and amplifying the inflammatory cascade. Additionally, IL-1&#x003b2; secretion can result in bone and cartilage breakdown. Other cytokines, such as TNF-alpha, IL-6, CXCL8, and cyclooxygenase 2 (COX-2), are also involved in the inflammatory response.<xref ref-type="bibr" rid="article-22376.r66">[66]</xref><xref ref-type="bibr" rid="article-22376.r67">[67]</xref><xref ref-type="bibr" rid="article-22376.r70">[70]</xref><xref ref-type="bibr" rid="article-22376.r74">[74]</xref><xref ref-type="bibr" rid="article-22376.r75">[75]</xref><xref ref-type="bibr" rid="article-22376.r76">[76]</xref></p>
          </list-item>
        </list>
        <p>Unlike most external stimuli that activate inflammatory cells by a carefully coordinated cell surface signal transduction&#x000a0;involving a cascade of tyrosine kinase phosphorylation, MSU crystals bypass&#x000a0;this process and directly activate second messenger systems.&#x000a0;</p>
        <table-wrap id="article-22376.table7" position="float" orientation="portrait">
          <caption>
            <title>Table 7.&#x000a0;Inflammatory Events in Acute Gout Flare</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">1. Deposition and release of urate microcrystals</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">2. Proinflammatory&#x000a0;coating (IgG, complement)</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">3.&#x000a0;Initial reaction with resident cells&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">4.&#x000a0;Activation of membrane signaling molecules&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">5. NLRP3 inflammasome activation: IL-1 beta release</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">6.&#x000a0;Release of cytokines and chemokines</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">7.&#x000a0;Activation of endothelial cell adhesion molecules</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">
<p>8.&#x000a0;Activation of neutrophils&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">9.&#x000a0;Phagocytosis of crystals by neutrophils</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">10. Cross-linking of inflammatory signaling proteins</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">
<p>11. Removal of crystal coating and phagolysosomal rupture, enzyme and mediator release&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td style="width: 657.812px;" rowspan="1" colspan="1">
<p>12. Resolution: aggregated NET formation, cytokines TGF-beta, MC-R,&#x000a0;PPAR-gamma, and AMPK activation.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Termination of The Acute Flare</bold>
</p>
        <p>Acute gout is&#x000a0;inherently self-limiting, even without intervention, typically&#x000a0;resolving spontaneously within a few days to a few weeks.&#x000a0;This phenomenon is intriguing, given the similarity in the molecular mediators of inflammation in gout and other arthropathies and the persistence of MSU crystals.</p>
        <p>Following MSU crystal ingestion, neutrophils undergo NETosis (neutrophil extracellular traps). These NETs aggregate and densely pack MSU crystals&#x000a0;while degrading the proinflammatory cytokines, including IL-&#x003b2;, TNF-&#x003b1;, and IL-6. The increased vascular permeability after acute synovitis allows increased entry of anti-inflammatory cytokines and crystal-coating molecules like apolipoprotein B (apoB). Coating with apoB and locally produced apoE and transforming growth factor &#x003b2; (TGF-&#x003b2;) inhibits neutrophil activation. Systemic anti-inflammatory mediators like melanocortins decrease joint inflammation by the macrophage melanocortin receptors (MCRs), and adenosine monophosphate-activated protein kinase inhibits NLRP3 expression, which inhibits the&#x000a0;cleavage of caspase-1 and secretion of IL-1&#x003b2;.<xref ref-type="bibr" rid="article-22376.r66">[66]</xref><xref ref-type="bibr" rid="article-22376.r67">[67]</xref><xref ref-type="bibr" rid="article-22376.r74">[74]</xref><xref ref-type="bibr" rid="article-22376.r76">[76]</xref>&#x000a0;</p>
        <p>
<bold>Advanced Gout</bold>
</p>
        <p>Tophi are deposits of MSU crystals associated with granulomatous inflammation. They are nests of crystals&#x000a0;surrounded by a corona zone composed of differentiated macrophages and multinucleated giant cells encased&#x000a0;within a fibrous layer. Proinflammatory cytokines like IL-1 and TNF-&#x003b1; are expressed within the corona. Aggregated NETs are also part of the tophus. The tophus is a dynamic chronic inflammatory response to MSU crystal deposition that is complex and organized.</p>
        <p>Tophi&#x000a0;are primarily&#x000a0;found in periarticular, articular, and subcutaneous areas, including cartilage, bone, joints, tendons, and skin, all rich in proteoglycan. The tissue reaction to tophus is generally chronic inflammation and&#x000a0;is both adaptive and innate immunity. Few patients with tophaceous gout also present with chronic gouty arthritis (chronic synovitis). There is a close relationship between MSU crystal deposits and the development of cartilage and bone erosions.<xref ref-type="bibr" rid="article-22376.r77">[77]</xref>&#x000a0;</p>
        <p>Tophi contribute to joint damage and bone erosion in gout.<xref ref-type="bibr" rid="article-22376.r78">[78]</xref>&#x000a0;At the bona and a tophus interface, MSU crystal deposits are surrounded by osteoclast-like cells.<xref ref-type="bibr" rid="article-22376.r79">[79]</xref>&#x000a0;T-cells within the tophus express the receptor activator of nuclear factor &#x003ba;B ligand (RANKL), continuing to bony erosions. Additionally, urate crystals decrease osteoblasts' function, viability, and differentiation and reduce osteoprotegerin expression. Hence, more&#x000a0;osteoclasts and reduced osteoblasts are present at the bone-tophus interphase.</p>
        <p>The double-contoured ultrasound sign is&#x000a0;observed in the superficial articular cartilage&#x000a0;of patients with chronic gout and represents the presence of urate deposits. Urate crystals degrade cartilage matrix by inducing nitric oxide generation and the expression of matrix metalloprotease 3. Consequently, joints with persistent crystals&#x000a0;experience ongoing progressive damage in the absence of acute flares.&#x000a0;</p>
      </sec>
      <sec id="article-22376.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>When examined under polarized light microscopy, MSU crystal deposition is typically described as a rod or long needle-shaped crystal with negative birefringence.<xref ref-type="bibr" rid="article-22376.r80">[80]</xref>&#x000a0;When viewed under&#x000a0;light microscopy, tophi exhibit&#x000a0;distinct zones: the crystalline center, the surrounding corona zone, and the fibrovascular zone. The corona zone contains multinucleated giant cells, histiocytes, and plasma cells.<xref ref-type="bibr" rid="article-22376.r81">[81]</xref></p>
      </sec>
      <sec id="article-22376.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Gout has been described as a chronic disease characterized by&#x000a0;4 distinct stages.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Asymptomatic hyperuricemia</p>
          </list-item>
          <list-item>
            <p>Acute gout attacks</p>
          </list-item>
          <list-item>
            <p>Intercritical period</p>
          </list-item>
          <list-item>
            <p>Chronic tophaceous gout.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Asymptomatic Hyperuricemia</bold>
</p>
        <p>The majority of patients with asymptomatic hyperuricemia never develop gout. The risk of an acute gout attack increases with the serum urate level. This stage ends with the occurrence of the first gout attack.</p>
        <p>
<bold>Acute Gout Attack</bold>
</p>
        <p>The initial manifestation of gout is an acute attack of arthritis, usually monoarticular, marked by the abrupt onset of severe pain and swelling. Maximum inflammation occurs within 12 to 24 hours. Gout flares are typically monoarticular, with 85% to 90% of cases occurring in the lower extremities.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref><xref ref-type="bibr" rid="article-22376.r82">[82]</xref>&#x000a0;The first metatarsophalangeal joint is the most commonly involved, with about 50% of initial attacks occurring&#x000a0;there and 90% of patients experiencing at least 1 attack in this joint.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref> The talar, subtalar, ankle, and knee can also be involved. In 3% to 14% of cases, the initial attack is polyarticular, causing some confusion.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref>&#x000a0;</p>
        <p>Although affliction of the joints mentioned above is common in gout,&#x000a0;healthcare professionals should&#x000a0;also&#x000a0;consider&#x000a0;other joints, specifically those with underlying osteoarthritis. Periarticular structures such as tendons and bursa may also be involved.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref>&#x000a0;While gout can occur in axial joints such as sacroiliac joints and the spine, this is much less common than peripheral involvement, leading to diagnostic confusion.<xref ref-type="bibr" rid="article-22376.r83">[83]</xref><xref ref-type="bibr" rid="article-22376.r84">[84]</xref>&#x000a0;Acute gouty arthritis may be associated with fever and leukocytosis, making it difficult to differentiate from septic arthritis. The initial attack resolves within 3 to 14 days, even without pharmacotherapy. Over time, gout flares&#x000a0;occur more frequently,&#x000a0;become less intense, and involve more joints.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref>&#x000a0;</p>
        <p>Polyarticular gout flares are more likely to occur in patients with longstanding disease. Initial presentation of polyarticular gout is more frequent in patients in whom gout and hyperuricemia arise secondary to lymphoproliferative or myeloproliferative disorders or in organ transplant recipients receiving tacrolimus or cyclosporine.<xref ref-type="bibr" rid="article-22376.r85">[85]</xref><xref ref-type="bibr" rid="article-22376.r86">[86]</xref>&#x000a0; Additionally, in South Africa, a polyarticular presentation in women, with only a small number starting with acute podagra. Rarely, patients may develop tophi without a history of acute gouty flares.</p>
        <p>Gout flares are more common at night and early morning when cortisol levels are low.<xref ref-type="bibr" rid="article-22376.r87">[87]</xref>&#x000a0;The pain is often sudden, waking the patient from sleep, or it may have developed gradually over a few hours before the presentation,&#x000a0;reaching&#x000a0;its maximum intensity of pain at 24 hours.<xref ref-type="bibr" rid="article-22376.r87">[87]</xref>&#x000a0;Signs of inflammation may extend beyond the joint involved, giving the impression of cellulitis with erythema and desquamation or dactylitis (sausage digit). The pain is usually severe and not responsive to usual home remedies; even touching the joint can be excruciatingly painful. Gout flare-ups often incite local inflammation, which presents as erythematous, swollen, and warm joints. The erythema over the affected joint during an attack is characteristic of gouty synovitis. Systemic inflammatory features may include fever, malaise, and fatigue.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref>&#x000a0;</p>
        <p>Around 60% of the patients experience a second attack within&#x000a0;1 year, and 80% within&#x000a0;3 years. Acute attacks can be precipitated by local trauma, alcohol binges, overeating or fasting, weight changes, use of diuretics, and initiation of urate-lowering drugs. In a hospital setting, postoperative status or acute severe medical illnesses such as myocardial infarction, exacerbation of congestive heart failure, or cerebrovascular accident may precipitate attacks.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref> It is not unusual for patients to&#x000a0;receive urate-lowering therapy (ULT) during hospitalization, possibly leading to a gout flare. Additionally, the spring season has reportedly been associated with increased gout attacks.&#x000a0;&#x000a0;</p>
        <p>Physical examination findings in gout align with the patient's history. The affected joint is typically red, swollen, warm, and tender.<xref ref-type="bibr" rid="article-22376.r88">[88]</xref>&#x000a0;The flare-up in patients with chronic gout may involve multiple joints, causing a systemic inflammatory response syndrome that may&#x000a0;mimic&#x000a0;sepsis.<xref ref-type="bibr" rid="article-22376.r89">[89]</xref>&#x000a0;Tophi, subcutaneous&#x000a0;deposits of urate which&#x000a0;form nodules, can be found in patients with persistent hyperuricemia. Tophi typically occur in the joints, ears, finger pads, tendons, and bursae.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref></p>
        <p>
<bold>Intercritical Gout</bold>
</p>
        <p>After resolving the acute attack, the patient enters the intercritical stage. Patients typically feel well during this stage without experiencing joint pain or swelling. Despite the apparent inactivity of&#x000a0;the disease, hyperuricemia persists, and crystal deposition continues.&#x000a0;Subclinical inflammation may be present in the joints during this period.</p>
        <p>
<bold>Chronic Tophaceous Gout</bold>
</p>
        <p>Patients with gout who are untreated or undertreated&#x000a0;may develop chronic tophaceous gout over several years, leading to gradual progressive joint destruction. Gouty tophi, which are foreign bodies&#x000a0;surrounded by&#x000a0;granulomas&#x000a0;containing deposits of MSU crystal, manifest as chalk-like subcutaneous nodules&#x000a0;beneath transparent skin with increased vascularity. These nodules may or may not drain.&#x000a0;While some patients may present with tophi as their initial symptom, chronic tophaceous gout usually develops&#x000a0;10 or more years after an acute attack. However, microtophi&#x000a0;can be observed&#x000a0;early in the disease, especially in patients with hyperuricemia. MSU crystal deposition is&#x000a0;evident in joints affected by osteoarthritis, primarily in the connective tissue and articular cartilage.</p>
        <p>Tophi may&#x000a0;occur intraarticularly, periarticularly, or extra-articularly, with common sites including the digits of hands and feet, knees, and the olecranon bursa. This&#x000a0;condition leads to destructive deforming arthritis, extensive bone destruction, and&#x000a0;severe deformities. Women develop tophaceous deposits on the Heberden nodes and Bouchard nodes. Finger pad tophi&#x000a0;were observed in 30%&#x000a0;of patients with chronic tophaceous gout. Postmenopausal women with CKD may exhibit finger pad tophi&#x000a0;before the onset of an acute attack.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref><xref ref-type="bibr" rid="article-22376.r2">[2]</xref><xref ref-type="bibr" rid="article-22376.r66">[66]</xref></p>
        <p>Tophaceous deposits have been&#x000a0;documented in&#x000a0;various uncommon sites, including the eye cornea and heart valves.&#x000a0;These deposits highlight the systemic nature of gout and its potential to affect diverse tissues and organs beyond the joints.</p>
      </sec>
      <sec id="article-22376.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Synovial Fluid Analysis</bold>
</p>
        <p>Monosodium urate crystal identification remains the gold standard for diagnosing gout.<xref ref-type="bibr" rid="article-22376.r80">[80]</xref> Gout flares are marked by MSU crystals in synovial fluid obtained from affected joints of bursas, visualized through direct examination of a fluid sample using compensated polarized light microscopy. The crystals are often intracellular, indicating active phagocytosis. This technique&#x000a0;can also identify uric acid crystals from tophaceous deposits and joints during the intercritical period.<xref ref-type="bibr" rid="article-22376.r90">[90]</xref>&#x000a0;During a gout flare-up, synovial fluid is usually yellow and cloudy, containing crystals and white blood cells (WBCs) with neutrophil predominance.</p>
        <p>In patients with septic arthritis, the synovial fluid will be more opaque, with a yellow-green appearance. Microscopic examination reveals a higher WBC count (&#x0003e;50000/microL) with a predominance of neutrophils. However, there is considerable overlap in WBC counts and neutrophil percentages&#x000a0;between patients with acute gouty arthritis and septic arthritis, making these parameters unreliable for diagnosis. Positive synovial fluid gram stains and cultures, along with low synovial fluid glucose levels, are common findings in septic arthritis. It is essential to&#x000a0;note that the presence of crystals&#x000a0;in synovial fluid analysis does not rule out septic arthritis, as&#x000a0;both conditions can coexist.<xref ref-type="bibr" rid="article-22376.r91">[91]</xref><xref ref-type="bibr" rid="article-22376.r92">[92]</xref></p>
        <p>Under polarizing microscopy, synovial fluid or tophus aspiration analysis reveals needle-shaped, negatively birefringent crystals.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref><xref ref-type="bibr" rid="article-22376.r3">[3]</xref><xref ref-type="bibr" rid="article-22376.r93">[93]</xref>&#x000a0;Arthrocentesis is&#x000a0;essential&#x000a0;to confirm the diagnosis and&#x000a0;differentiate it from other conditions such as septic arthritis, Lyme disease, or pseudogout (caused by calcium pyrophosphate crystals).<xref ref-type="bibr" rid="article-22376.r93">[93]</xref></p>
        <p>
<bold>Laboratory Study</bold>
</p>
        <p>The examination usually reveals elevations in the WBC, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) during acute gouty arthritis. These features are nonspecific and do not confirm or differentiate the diagnosis from septic arthritis.<xref ref-type="bibr" rid="article-22376.r91">[91]</xref></p>
        <p>During acute gouty arthritis, the serum urate level may be high, normal, or low. About 50% of patients with acute gouty arthritis will not have an elevated serum uric acid. Serum uric acid measurement during an acute attack is of no diagnostic value; it is most useful when checked after the resolution of the flare. Hyperuricemia is helpful in the clinical diagnosis of gout in symptomatic patients, but hyperuricemia alone does not confirm the diagnosis. Asymptomatic hyperuricemia is not uncommon in the general population. Persistently low serum uric acid concentrations make the diagnosis of gout unlikely.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref>&#x000a0;In patients suspected of gout based on clinical features, an elevated serum uric acid level (&#x0003e;6.8 mg/dL) can support the diagnosis but is neither diagnostic nor required to establish the diagnosis. The most accurate time to assess serum urate level to establish a baseline value is&#x000a0;2 weeks or more after a gout flare has subsided.</p>
        <p>Urinary fractional excretion of uric acid can be measured, especially in young populations with nonspecific causes of hyperuricemia. The measurement&#x000a0;can help differentiate between overproduction or underexcretion of uric acid and can guide therapy.</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>Although not routinely used, ultrasonography and dual-energy CT (DECT) can assist in diagnosing gout.<xref ref-type="bibr" rid="article-22376.r94">[94]</xref><xref ref-type="bibr" rid="article-22376.r95">[95]</xref><xref ref-type="bibr" rid="article-22376.r96">[96]</xref><xref ref-type="bibr" rid="article-22376.r97">[97]</xref>&#x000a0;On ultrasound, MSU deposition&#x000a0;appears as a hyperechoic enhancement over the cartilage, known as&#x000a0;the double contour sign. DECT can identify urate deposits&#x000a0;based&#x000a0;on the beam attenuation after exposure to&#x000a0;2 different X-ray spectra.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref><xref ref-type="bibr" rid="article-22376.r3">[3]</xref>&#x000a0;In a pooled analysis, the ultrasound double contour sign had a sensitivity of 83% and a specificity of 76%, while DECT had a sensitivity of 87% and a specificity of 84% for diagnosing gout.<xref ref-type="bibr" rid="article-22376.r95">[95]</xref>&#x000a0;A meta-analysis of&#x000a0;ultrasound's diagnostic accuracy, which included features like the double contour sign, tophus, or bony erosion, showed a sensitivity&#x000a0;of 65.1% and specificity&#x000a0;of 89% for a diagnosis of gout.<xref ref-type="bibr" rid="article-22376.r98">[98]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22376.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Specific goals guide the treatment of gout. During acute flares, the&#x000a0;primary objective is to alleviate inflammation and symptoms. In the&#x000a0;long term, the goal shifts toward&#x000a0;reducing serum urate levels to suppress flare-ups and regression of tophi.<xref ref-type="bibr" rid="article-22376.r3">[3]</xref><xref ref-type="bibr" rid="article-22376.r99">[99]</xref><xref ref-type="bibr" rid="article-22376.r100">[100]</xref></p>
        <p>
<bold>General Principles of Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Early on, introducing treatment for a gout flare leads to a more rapid resolution of symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The duration of gout flare therapy ranges from a few days to several weeks, depending on the timing of treatment initiation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Anti-inflammatory gout flare prophylaxis&#x000a0;should&#x000a0;generally be continued during the early months (up to 6 months) of ULT.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients receiving ULT at the time of gout flare, the urate-lowering medication should be continued without interruption as there is no benefit to temporary discontinuation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The presence of tophi indicates initiating long-term ULT either during or following the resolution of a gout flare to reverse or prevent joint damage and chronic gouty arthritis.</p>
          </list-item>
        </list>
        <p>
<bold>Acute Gout Flare</bold>
</p>
        <p>The management of acute flares of gouty arthritis aims&#x000a0;to&#x000a0;decrease&#x000a0;inflammation and resulting pain. Treatment should&#x000a0;commence&#x000a0;within the first 24 hours of onset to reduce the severity and duration of the flare-up if possible.<xref ref-type="bibr" rid="article-22376.r10">[10]</xref>&#x000a0;Nonpharmacological management, such as rest with topical application of ice packs&#x000a0;<xref ref-type="bibr" rid="article-22376.r101">[101]</xref>&#x000a0;can be combined with medications that reduce inflammation.<xref ref-type="bibr" rid="article-22376.r102">[102]</xref> First-line treatments for gout flares are nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or systemic glucocorticoids.<xref ref-type="bibr" rid="article-22376.r103">[103]</xref> The length of treatment should be at least 7 to 10 days to prevent rebound flare-ups.<xref ref-type="bibr" rid="article-22376.r104">[104]</xref>&#x000a0;Early initiation of NSAIDs may lead to the resolution of the attack with a single dose.</p>
        <p>
<bold>NSAIDs</bold>
</p>
        <p>NSAIDs are most effective when therapy is initiated within 48 hours of the onset of gout symptoms. Indomethacin and naproxen are the more potent NSAIDs for gout, although many other commonly used NSAIDs exist. NSAID names and dosing are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Indomethacin 50 mg 3 times daily</p>
          </list-item>
          <list-item>
            <p>Naproxen 500 mg twice daily</p>
          </list-item>
          <list-item>
            <p>Naproxen 500 mg twice daily</p>
          </list-item>
          <list-item>
            <p>Ibuprofen 800 mg 3 times daily</p>
          </list-item>
          <list-item>
            <p>Diclofenac 50 mg 2 to 3 times daily</p>
          </list-item>
          <list-item>
            <p>Celecoxib 200 mg twice daily</p>
          </list-item>
        </list>
        <p>Typically, NSAID treatment for gout flare lasts for&#x000a0;5 to&#x000a0;7 days. There is no significant preference for one NSAID over another, but high-dose, fast-acting NSAIDs such as naproxen or diclofenac are options. Indomethacin is not preferable due to its toxicity profile.<xref ref-type="bibr" rid="article-22376.r10">[10]</xref>&#x000a0;NSAIDs are usually given in full doses for the first&#x000a0;3 days and then tapered according to the clinical improvement. COX2 selective inhibitors like celecoxib can be&#x000a0;used to reduce adverse GI effects.</p>
        <p>Contraindications for the use of NSAIDs include active duodenal or gastric ulcer, cardiovascular disease (uncontrolled&#x000a0;HTN&#x000a0;or CHF), NSAID allergy, and CKD with creatinine clearance (CrCl) of less than 60 ml/minute per 1.73 square meters. Aspirin is not&#x000a0;recommended&#x000a0;for treating gout flares due to the paradoxical effects of salicylic acid on serum urate levels.<xref ref-type="bibr" rid="article-22376.r105">[105]</xref><xref ref-type="bibr" rid="article-22376.r106">[106]</xref>&#x000a0;This paradoxical effect results from uricosuria at higher doses&#x000a0;and renal uric acid retention at lower doses (less than 2 to 3 g/day).<xref ref-type="bibr" rid="article-22376.r107">[107]</xref><xref ref-type="bibr" rid="article-22376.r108">[108]</xref></p>
        <p>
<bold>Oral Glucocorticoids</bold>
</p>
        <p>Glucocorticoids are recommended&#x000a0;for gout patients with contraindications to NSAIDs and colchicine, and they are also preferred for patients with renal insufficiency. The initial dose for a gout flare is:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prednisolone or prednisone 30 to 40 mg once daily or divided into twice-daily doses until resolution begins. Taper the dose over the next 5 to 10 days.</p>
          </list-item>
        </list>
        <p>This has been proven to be at least comparable to NSAID efficacy. High starting doses of systemic steroids (&#x0003e;0.5 mg/kg body weight) are required for acute gout, especially in patients with a polyarticular presentation. A depot preparation for triamcinolone (60mg once) or methylprednisolone has been&#x000a0;reported to be effective.<xref ref-type="bibr" rid="article-22376.r109">[109]</xref><xref ref-type="bibr" rid="article-22376.r110">[110]</xref>&#x000a0;However, the dose may need to be repeated at intervals of 48 hours to achieve resolution of the flare. Glucocorticoids can be administered intra-articularly for a monoarticular gout flare-up or orally for polyarticular flare-ups. The efficacy of glucocorticoids is similar to or superior to other agents and has no greater risk of adverse effects in most patients.<xref ref-type="bibr" rid="article-22376.r111">[111]</xref><xref ref-type="bibr" rid="article-22376.r112">[112]</xref><xref ref-type="bibr" rid="article-22376.r113">[113]</xref></p>
        <p>In patients with an unclear diagnosis of an acute gout flare, arthrocentesis and synovial fluid analysis should be performed, and oral and intra-articular glucocorticoids&#x000a0;should&#x000a0;be avoided until the results are available. Initiation of other agents, such as NSAIDs or colchicine, should be considered. Frequent adverse effects of moderate- to high-dose, short-term glucocorticoid use include hyperglycemia, fluid retention, increased blood pressure, and mood changes. Repeated and regular courses of glucocorticoids should be avoided to limit adverse effects.</p>
        <p>In patients with concomitant or suspected infections, uncontrolled diabetes mellitus, prior glucocorticoid intolerance, and post-operative status, glucocorticoids may heighten the risk of impaired wound healing. Careful consideration of these factors is crucial when determining the appropriate course of treatment for patients with gout flares.</p>
        <p>
<bold>Parenteral Glucocorticoids</bold>
</p>
        <p>Intravenous or intramuscular glucocorticoids are suggested&#x000a0;for patients who are not candidates for intraarticular glucocorticoid injection or cannot take oral medications. A typical methylprednisolone dose is 20 mg intravenously twice daily, with a stepwise reduction and rapid transition to oral prednisone when improvement begins. Adrenocorticotropic hormone (ACTH) is also efficacious for treating gout flare, but limited availability and high cost restrict its use.</p>
        <p>
<bold>Colchicine</bold>
</p>
        <p>Colchicine, derived from the <italic toggle="yes">Colchicum autumnale</italic> plant and&#x000a0;with a history spanning over 3500 years,<xref ref-type="bibr" rid="article-22376.r114">[114]</xref><italic toggle="yes">&#x000a0;</italic>has proven&#x000a0;comparable in&#x000a0;efficacy to other agents&#x000a0;when taken within 24 hours of gout flare onset. In a randomized control trial, colchicine reduced&#x000a0;pain by over 50% at 24 hours compared to a placebo. The lipophilic nature of colchicine makes it readily bioavailable for cellular uptake after oral administration. The primary target of colchicine is tubulin, and it is metabolized through&#x000a0;hepatic elimination.</p>
        <p>Colchicine acts by binding tightly to unpolymerised tubulin and forms a colchicine-tubulin complex&#x000a0;that regulates microtubule and cytoskeletal function. This&#x000a0;regulation extends to diverse cellular processes, including&#x000a0;cell proliferation,&#x000a0;gene expression, signal transduction, chemotaxis, and neutrophil secretion of granule contents. Furthermore, colchicine decreases neutrophil adhesion by suppressing E-selectin redistribution in the endothelial membrane.</p>
        <p>EULAR consensus guidelines&#x000a0;recommend a maximum of 3 doses of 0.5mg of colchicine daily for treating acute gout. The total colchicine dose should not exceed 1.8 mg on day 1, 1.2 mg for the first dose followed by 0.6 mg an hour later [US Food and Drug Administration (FDA) approved dose] or 0.6 mg&#x000a0;3 times on the first day.<xref ref-type="bibr" rid="article-22376.r115">[115]</xref>&#x000a0;On subsequent days, colchicine should be taken once or twice daily until the gout flare resolves.<xref ref-type="bibr" rid="article-22376.r116">[116]</xref></p>
        <p>A reduced dose of colchicine may be required for patients with diminished hepatic or renal function or those at risk of potential drug interactions. Colchicine toxicity can occur with ABCB1 inhibitors like cyclosporin and clarithromycin; neuromyopathy may develop weeks after initiating cyclosporin. High-dose colchicine regimens should be&#x000a0;avoided due to their high toxicity. Adverse effects of colchicine&#x000a0;include gastrointestinal (GI) symptoms like nausea and diarrhea, myotoxicity, and myelosuppression (leukopenia, thrombocytopenia, and aplastic anemia).<xref ref-type="bibr" rid="article-22376.r117">[117]</xref>&#x000a0;The most common adverse effects are abdominal cramping and diarrhea.<xref ref-type="bibr" rid="article-22376.r115">[115]</xref><xref ref-type="bibr" rid="article-22376.r118">[118]</xref>&#x000a0;Intravenous colchicine is strongly&#x000a0;discouraged&#x000a0;due to serious adverse effects, including death, and it is no longer approved by the FDA in the US.</p>
        <p>Colchicine dosing adjustments for certain high-risk groups of patients should follow the guidelines&#x000a0;outlined in the manufacturer's FDA-approved information. Typically,&#x000a0;a maximum of 0.3 mg dose is administered on the day of a gout flare, and the dose is not repeated for at least&#x000a0;3 to&#x000a0;7 days or&#x000a0;longer in such patients. The high-risk groups include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals who have used&#x000a0;colchicine prophylaxis&#x000a0;in the&#x000a0;last 14 days possess normal hepatic and renal function and&#x000a0;have taken a medication that inhibits&#x000a0;P-glycoprotein or is a potent inhibitor of CYP3A4 within the previous 14 days.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals who have used&#x000a0;colchicine prophylaxis&#x000a0;in the&#x000a0;last 14 days,&#x000a0;regardless&#x000a0;of hepatic and renal status, and have taken a medication that is a moderate CYP3A4 inhibitor within the same timeframe.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals&#x000a0;with advanced hepatic or renal impairment (Child-Pugh C cirrhosis or equivalent CrCl of &#x0003c;30 mL/min), regardless of recent colchicine use.&#x000a0;</p>
          </list-item>
        </list>
        <p>Colchicine&#x000a0;exhibits&#x000a0;interesting effects beyond&#x000a0;treating and&#x000a0;preventing&#x000a0;gouty arthritis flares. Research suggests it has a beneficial effect on cardiovascular events.<xref ref-type="bibr" rid="article-22376.r114">[114]</xref><xref ref-type="bibr" rid="article-22376.r119">[119]</xref><xref ref-type="bibr" rid="article-22376.r120">[120]</xref>&#x000a0;A population study linked colchicine use in patients with gout to reduced cardiovascular events and all-cause mortality.<xref ref-type="bibr" rid="article-22376.r121">[121]</xref>&#x000a0;In a randomized, double-blind trial involving post-MI patients within 30 days (n = 4,745), low-dose colchicine use lowered the risk of cardiovascular events (resuscitated cardiac arrest, MI, stroke, and angina leading to revascularization) compared to placebo: 5.5% with colchicine versus 7.1% with placebo;&#x000a0;HR 0.77 (95% CI 0.61-0.96; P=0.02).<xref ref-type="bibr" rid="article-22376.r122">[122]</xref>&#x000a0;While&#x000a0;colchicine&#x000a0;did not affect outcomes&#x000a0;like death from cardiovascular causes, resuscitated cardiac arrest, or MI,&#x000a0;it notably reduced&#x000a0;stroke and angina, leading to coronary revascularization.</p>
        <p>
<bold>Prophylaxis For Acute Gout</bold>
</p>
        <p>The subclinical joint inflammation in gout justifies colchicine prophylaxis, as acute gout flares&#x000a0;are ULT's most common adverse effect. For prophylaxis, low-dose colchicine therapy is the first choice.<xref ref-type="bibr" rid="article-22376.r123">[123]</xref><xref ref-type="bibr" rid="article-22376.r124">[124]</xref>&#x000a0;It is commenced 1 or 2 weeks before using urate-lowering drugs and continues for up to 6 months after normalizing uric acid levels or until the clinically visible tophi are resolved.<xref ref-type="bibr" rid="article-22376.r124">[124]</xref><xref ref-type="bibr" rid="article-22376.r123">[123]</xref>&#x000a0; Low-dose NSAIDs and low-dose corticosteroids can be used but&#x000a0;carry more toxicity.<xref ref-type="bibr" rid="article-22376.r125">[125]</xref> The recommended colchicine dosage is 0.6 mg once or twice daily without renal or hepatobiliary compromise. In patients with renal impairment, the colchicine dose may be reduced to 0.3 mg daily or 0.6 mg every other day.</p>
        <p>
<bold>Interleukin-1 Inhibition</bold>
</p>
        <p>IL-1 antagonists have shown efficacy in refractory cases of gouty arthritis. Anakinra, a soluble IL1 receptor antagonist, is administered at 100 mg/day subcutaneously for 3 days&#x000a0;<xref ref-type="bibr" rid="article-22376.r126">[126]</xref><xref ref-type="bibr" rid="article-22376.r127">[127]</xref>&#x000a0;or a&#x000a0;single&#x000a0;dose of IL-1 beta monoclonal antibody, canakinumab.<xref ref-type="bibr" rid="article-22376.r128">[128]</xref><xref ref-type="bibr" rid="article-22376.r129">[129]</xref>&#x000a0;The subcutaneous&#x000a0;dose of 150 mg&#x000a0;canakinumab was more effective than a single-dose&#x000a0;intramuscular (IM) dose of triamcinolone acetonide, although the risk-benefit ratio is uncertain.</p>
        <p>
<bold>Urate lowering therapy (ULT)</bold>
</p>
        <p>
<bold>Non-pharmacologic treatment</bold>
</p>
        <p>Gout is associated with several comorbidities, including obesity.<xref ref-type="bibr" rid="article-22376.r38">[38]</xref>&#x000a0;In a study examining the association between obesity and gout, adults aged 40 to 75 years (n = 11,079) in NHANES 2007 to 2014 were&#x000a0;categorized into 4 groups: stable obese,&#x000a0;weight&#x000a0;gain, weight loss, and those&#x000a0;maintaining a normal BMI over time (reference group).<xref ref-type="bibr" rid="article-22376.r40">[40]</xref>&#x000a0;Among those with stable obesity, the risk of gout was the highest, with an HR of 1.84 (95% CI 1.08-3.14). Patients who gained weight as adults also&#x000a0;exhibited an increased risk of gout with HR of 1.65 (95% CI 1.19-2.29).</p>
        <p>Diet can affect serum uric acid levels. Weight loss and dietary adjustments can reduce serum uric acid by 1 to 2 mg/dL. Foods high in purines, such as organ meats, shellfish, and beer, can elevate uric acid levels. Soft drinks containing high-fructose corn syrup are associated with an increased risk of gout;<xref ref-type="bibr" rid="article-22376.r14">[14]</xref><xref ref-type="bibr" rid="article-22376.r15">[15]</xref>&#x000a0;therefore, reducing their intake can help&#x000a0;reduce serum uric acid. The DASH diet has been&#x000a0;proven to lower serum uric acid compared to a standard Western diet, making it beneficial for gout management.<xref ref-type="bibr" rid="article-22376.r18">[18]</xref>&#x000a0;Consuming&#x000a0;at least 500 mg daily of vitamin C has also been shown to decrease serum uric acid levels and lower the risk of incident gout.<xref ref-type="bibr" rid="article-22376.r20">[20]</xref><xref ref-type="bibr" rid="article-22376.r21">[21]</xref><xref ref-type="bibr" rid="article-22376.r22">[22]</xref><xref ref-type="bibr" rid="article-22376.r23">[23]</xref><xref ref-type="bibr" rid="article-22376.r24">[24]</xref>&#x000a0;Studies have shown that higher doses of vitamin C correspond to reduced risk of gout in men.<xref ref-type="bibr" rid="article-22376.r23">[23]</xref>&#x000a0;Cherry consumption has&#x000a0;also been linked&#x000a0;to lowered serum uric acid levels<xref ref-type="bibr" rid="article-22376.r25">[25]</xref>&#x000a0;and&#x000a0;a&#x000a0;decreased risk of recurrent gout attacks<xref ref-type="bibr" rid="article-22376.r26">[26]</xref>.</p>
        <p>
<bold>Pharmacologic</bold>
</p>
        <p>The 2020 American College of Rheumatology Guideline for managing gout&#x000a0;<xref ref-type="bibr" rid="article-22376.r100">[100]</xref>&#x000a0;advises&#x000a0;against&#x000a0;initiating&#x000a0;ULT after the first&#x000a0;episode of acute gouty arthritis. ULT should not be initiated&#x000a0;in patients with asymptomatic hyperuricemia. The guidelines provide specific criteria for initiating ULT, including the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Frequent or disabling gout flares (&#x02265;2 yearly) that are difficult to treat</p>
          </list-item>
          <list-item>
            <p>Gout with chronic kidney disease (stage 3 or higher)</p>
          </list-item>
          <list-item>
            <p>Tophus diagnosis on physical examination or imaging</p>
          </list-item>
          <list-item>
            <p>Past urolithiasis</p>
          </list-item>
          <list-item>
            <p>Chronic tophaceous gout</p>
          </list-item>
        </list>
        <p>The decision to initiate&#x000a0;ULT should be individualized. For instance, in a younger patient with&#x000a0;their first gout attack with&#x000a0;elevated serum uric acid levels, the likelihood of future gout attacks and progressive joint damage with tophi is higher, making it&#x000a0;prudent to start ULT. Conversely, in an elderly patient with gout, multiple comorbidities, and taking multiple medications, the decision to treat may be more nuanced, and careful consideration should be given in this scenario. It is essential to note that&#x000a0;the guidelines are to&#x000a0;provide guidance but not dictate therapy.</p>
        <p>ULT is started at a low dose to monitor the side effects and&#x000a0;treatment response. Dose adjustments are made every 2 to 6 weeks to achieve serum urate levels of less than 6 mg/dL or 5 mg/dL in patients with tophi.<xref ref-type="bibr" rid="article-22376.r100">[100]</xref><xref ref-type="bibr" rid="article-22376.r130">[130]</xref>&#x000a0;The 2020 American College of Rheumatology Guideline conditionally recommends starting ULT during acute gout flares, with some evidence&#x000a0;supporting its safety with medications like&#x000a0;allopurinol&#x000a0;<xref ref-type="bibr" rid="article-22376.r131">[131]</xref><xref ref-type="bibr" rid="article-22376.r132">[132]</xref>&#x000a0;and febuxostat.<xref ref-type="bibr" rid="article-22376.r133">[133]</xref>&#x000a0;However, initiating therapy during an acute attack might pose challenges regarding patient compliance, especially considering that patients experiencing acute flares are often hospitalized for the first time.</p>
        <p>During the initiation of ULT, there is an increased risk of gout flare-ups. As a prophylactic measure, colchicine is recommended for&#x000a0;3 months after achieving the serum urate goal in patients without tophi or&#x000a0;6 months&#x000a0;in those with tophi. This strategy helps to minimize the risk of flare-ups during this critical period.<xref ref-type="bibr" rid="article-22376.r100">[100]</xref></p>
        <p>ULT can be categorized into&#x000a0;3 classes based on their mechanisms:</p>
        <p><bold>Xanthine oxidase inhibitors (XOI)</bold>&#x000a0;</p>
        <p>XOIs work by inhibiting uric acid synthesis. This class includes allopurinol and febuxostat. Allopurinol is the recommended first-line pharmacologic ULT in gout.<xref ref-type="bibr" rid="article-22376.r100">[100]</xref>&#x000a0;Physicians should regularly monitor liver enzymes, renal function, and blood count. Adverse effects from allopurinol can range from skin rashes to life-threatening severe allopurinol hypersensitivity, especially in HLA-B*5801-positive patients.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref><xref ref-type="bibr" rid="article-22376.r100">[100]</xref></p>
        <p>
<bold>Allopurinol</bold>
</p>
        <p>Allopurinol is converted to its active metabolite oxypurinol in the liver and has a half-life of 24 hours. The initial allopurinol dose is 100 mg daily in patients with CrCl more significant than 60 mL/min and is titrated upward by 100 mg every 2 to 4 weeks. A daily dose of 300 mg of allopurinol reduces serum urate levels in 33% of the population. Allopurinol can be increased above 300 mg daily to&#x000a0;achieve the target serum uric acid.</p>
        <p>Allopurinol is taken once daily. Medications like allopurinol and oxypurinol lower the serum urate by a dual action of&#x000a0;inhibiting xanthine oxidase inhibitor&#x000a0;and by competing with phosphoribosylpyrophosphate in the salvage pathway and&#x000a0;through suppressive effects of drug nucleotides on aminotransferase activity. Allopurinol also nonselectively inhibits pyrimidine metabolism. In patients with stage 3 or greater CKD, the starting dose of allopurinol should be 50 mg daily.<xref ref-type="bibr" rid="article-22376.r100">[100]</xref>&#x000a0;</p>
        <p>Adverse effects associated with allopurinol include the potential to trigger gout flares, pruritic and maculopapular rashes, leukopenia, thrombocytopenia, diarrhea, and severe cutaneous adverse reactions. Bone marrow suppression is uncommon but may occur at very high doses or in patients with CKD. Allopurinol can lead to a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, a life-threatening reaction to allopurinol.</p>
        <p>Major hypersensitivity reactions like Steven-Johnson syndrome or toxic epidermal necrolysis may occur in major allopurinol hypersensitivity syndrome (AHS). The highest risk for AHS occurs in the first 60 days after initiating allopurinol therapy. Patients who carry the HLA-B*5801 allele are at increased risk for developing severe hypersensitivity reactions, which are&#x000a0;more common in people of Han Chinese, Korean, or Thai descent.<xref ref-type="bibr" rid="article-22376.r100">[100]</xref><xref ref-type="bibr" rid="article-22376.r134">[134]</xref>&#x000a0;Testing&#x000a0;for this allele is advisable in high-risk patients. Starting at a low dose and gradually&#x000a0;increasing it can&#x000a0;decrease the risk of adverse reactions. The recommended starting dose is 1.5 mg per unit of estimated GFR.<xref ref-type="bibr" rid="article-22376.r135">[135]</xref>&#x000a0;Interestingly, allopurinol can be safely increased above 300 mg daily,&#x000a0;even in patients with CKD, to achieve the target serum uric acid.<xref ref-type="bibr" rid="article-22376.r136">[136]</xref></p>
        <p>Allopurinol can&#x000a0;enhance the cytolytic and immunosuppressive effects of azathioprine and 6-mercaptopurine (6-MP),&#x000a0;as these drugs are partially&#x000a0;metabolized by xanthine oxidase.<xref ref-type="bibr" rid="article-22376.r137">[137]</xref>&#x000a0;Therefore, allopurinol should be avoided in patients&#x000a0;undergoing treatment&#x000a0;with these agents.<xref ref-type="bibr" rid="article-22376.r138">[138]</xref>&#x000a0;Additionally, in patients&#x000a0;on warfarin, their anticoagulation status must be carefully monitored when allopurinol is prescribed.</p>
        <p>
<bold>Febuxostat</bold>
</p>
        <p>Febuxostat is a selective XOI that occupies the access channel to the molybdenum-pterin active site of the enzyme. Renal elimination plays a minor role in febuxostat pharmacokinetics. FDA approval for febuxostat in treating patients with gout&#x000a0;and hyperuricemia&#x000a0;includes initial&#x000a0;daily doses of 40 mg. If the urate levels do not normalize&#x000a0;within&#x000a0;2 weeks, the dosage is increased to 80 mg daily. Studies have demonstrated&#x000a0;the superior effectiveness of febuxostat over allopurinol (maximum dose of 300 mg daily).<xref ref-type="bibr" rid="article-22376.r139">[139]</xref><xref ref-type="bibr" rid="article-22376.r140">[140]</xref>&#x000a0;However, febuxostat may be more common with allopurinol than cardiovascular and hepatic abnormalities. In patients with CKD,&#x000a0;febuxostat exhibits a more potent&#x000a0;urate-lowering&#x000a0;than allopurinol. Febuxostat&#x000a0;has a&#x000a0;distinct chemical structure, making it an option for patients who have experienced hypersensitivity reactions to allopurinol. Patients taking azathioprine, 6-MP, and theophylline are considered contraindications&#x000a0;for the use of febuxostat.</p>
        <p>In the CARES trial, which focused on cardiovascular safety in patients with gout and a history of cardiovascular disease, febuxostat and&#x000a0;allopurinol were compared.<xref ref-type="bibr" rid="article-22376.r141">[141]</xref>&#x000a0;The primary endpoint, a composite of cardiovascular death, nonfatal MI, nonfatal stroke, or unstable angina requiring revascularization, showed no significant difference between the 2 drugs. However, febuxostat was associated with an increased risk of cardiovascular death (HR of 1.34, 95% CI 1.03-1.73, P=0.03) and higher all-cause mortality (HR of 1.22, 95% CI 1.01-1.47, P=0.04). Some population studies have also shown an increased risk of cardiovascular events and death.<xref ref-type="bibr" rid="article-22376.r142">[142]</xref><xref ref-type="bibr" rid="article-22376.r143">[143]</xref>&#x000a0;However, some studies do not show an increased risk of cardiovascular events, including a randomized, open-label noninferiority study,<xref ref-type="bibr" rid="article-22376.r144">[144]</xref>&#x000a0;2 population studies,<xref ref-type="bibr" rid="article-22376.r145">[145]</xref><xref ref-type="bibr" rid="article-22376.r146">[146]</xref>&#x000a0;and a systematic review<xref ref-type="bibr" rid="article-22376.r147">[147]</xref>. In a follow-up investigation of the CARES trial, patients who discontinued ULT experienced increased cardiovascular events and deaths at 30 days and 6 months.<xref ref-type="bibr" rid="article-22376.r148">[148]</xref></p>
        <p>Allopurinol and febuxostat are similarly effective, although some data suggest that febuxostat may be more effective in patients with CKD. In a comparative noninferiority trial of allopurinol and febuxostat, where at least 33% of patients had stage 3 CKD, both drugs showed similar efficacy in&#x000a0;managing flares and reducing serum uric acid levels to the target range.<xref ref-type="bibr" rid="article-22376.r149">[149]</xref></p>
        <p>XOIs have&#x000a0;demonstrated various effects, particularly&#x000a0;in population studies&#x000a0;focusing on&#x000a0;cardiovascular disease.<xref ref-type="bibr" rid="article-22376.r150">[150]</xref>&#x000a0;The theory is that chronic hyperuricemia and MSU deposition result in chronic inflammation, thereby&#x000a0;enhancing&#x000a0;the progression of atherosclerosis. Notably, allopurinol has been associated with a modest&#x000a0;reduction in all-cause mortality&#x000a0;among patients with gout.<xref ref-type="bibr" rid="article-22376.r151">[151]</xref><xref ref-type="bibr" rid="article-22376.r152">[152]</xref>&#x000a0;A case-matched cohort study conducted in&#x000a0;Taiwan revealed that patients with gout&#x000a0;faced an increased risk of cardiovascular and all-cause mortality. However, ULT treatment was&#x000a0;linked to a reduced risk of cardiovascular (HR 0.29, 95% CI 0.11-0.80) and all-cause mortality (HR 0.47, 95% CI 0.29-0.79).<xref ref-type="bibr" rid="article-22376.r153">[153]</xref>&#x000a0;Allopurinol use was correlated with a&#x000a0;lower risk of developing incident atrial fibrillation.<xref ref-type="bibr" rid="article-22376.r154">[154]</xref>&#x000a0;</p>
        <p>ULT may also slow the progression of CKD,<xref ref-type="bibr" rid="article-22376.r155">[155]</xref><xref ref-type="bibr" rid="article-22376.r156">[156]</xref><xref ref-type="bibr" rid="article-22376.r157">[157]</xref><xref ref-type="bibr" rid="article-22376.r158">[158]</xref>&#x000a0;and allopurinol is associated with a lower risk of incident renal disease in elderly patients compared to febuxostat.<xref ref-type="bibr" rid="article-22376.r159">[159]</xref>&#x000a0;Literature suggests that ULT in gout patients might affect outcomes, including dementia, erectile dysfunction, and other comorbidities. While some controlled trials&#x000a0;have explored the effect of allopurinol on the incident rate of cardiovascular events, renal disease, and DM, these studies were performed in at-risk patients, not&#x000a0;specifically in those&#x000a0;with gout. Therefore, the relevance of these findings to patients with gout remains unclear.&#x000a0;</p>
        <p>
<bold>Uricosuric Drugs&#x000a0;</bold>
</p>
        <p>The uricosuric agents work by increasing renal urate clearance.<xref ref-type="bibr" rid="article-22376.r1">[1]</xref><xref ref-type="bibr" rid="article-22376.r66">[66]</xref>&#x000a0;Patients with low or normal urinary uric acid excretion in the presence of hyperuricemia are potential candidates for uricosuric therapy. Drugs in this class include probenecid and lesinurad (withdrawn from the US market). These agents&#x000a0;inhibit URAT1 at the apical membrane of the renal proximal tubule epithelial cell. However, they are ineffective as monotherapy in patients with low creatinine clearance (&#x0003c;30 ml/min) and contraindicated&#x000a0;in patients with a history of nephrolithiasis.<xref ref-type="bibr" rid="article-22376.r160">[160]</xref>&#x000a0;</p>
        <p>Probenecid, the only agent approved&#x000a0;as a monotherapy, is initiated at 250 mg twice daily. Dose&#x000a0;adjustments are&#x000a0;made according to the serum urate concentration level, with increments every few weeks. The usual maintenance dose&#x000a0;ranges from 500 to 1000 mg (taken 2 to 3 times daily), aiming&#x000a0;to&#x000a0;achieve target urate levels of less than 6 mg/dL (&#x0003c;357 &#x000b5;mol/L).</p>
        <p>The significant side effects of uricosuric drugs are the precipitation of a gout flare, uric acid urolithiasis, gastrointestinal intolerance, and rash. Uricosuric agents are not appropriate for patients with CKD&#x000a0;and a creatinine clearance of less than 60 mL/min. Patients with tophi are best treated with&#x000a0;XOIs or pegloticase.</p>
        <p>
<bold>Uricase Pegloticase (urate oxidase)</bold>
</p>
        <p>Uricase is present in nonprimates and lower primates. Pegloticase, a pegylated recombinant form of uricase, is a potent agent that rapidly reduces serum urate levels by directly degrading uric acid&#x000a0;into highly soluble allantoin. Polyethylene glycol (PEG) molecules are attached to the recombinant porcine-baboon uricase in a process known as PEGylation.This process extends the PEG molecule's half-life to days or weeks and decreases but does not eliminate immunogenicity.<xref ref-type="bibr" rid="article-22376.r161">[161]</xref>&#x000a0;</p>
        <p>Pegloticase is reserved for patients with refractory gout, usually&#x000a0;those with a high tophaceous burden. Patients must discontinue ULT while starting this medication because&#x000a0;antibodies against pegloticase&#x000a0;may develop. Pegloticase is administered as intravenous infusions every&#x000a0;2 weeks, and before each infusion, serum urate levels should be monitored to confirm urate-lowering efficacy. If the serum uric acid&#x000a0;rises&#x000a0;above 4 mg/dL, the infusions should be stopped, indicating that the patient is&#x000a0;developing&#x000a0;antibodies to pegloticase, which could lead to infusion reactions.</p>
        <p>Pegloticase has effectively lowered serum uric acid in patients with refractory gout, as evidenced by&#x000a0;short and long-term clinical trials.<xref ref-type="bibr" rid="article-22376.r162">[162]</xref><xref ref-type="bibr" rid="article-22376.r163">[163]</xref>&#x000a0;Phase 3 studies revealed complete resolution of&#x000a0;1 or more tophi in 20% of patients by 13 weeks and lowered uric acid levels to less than 6 mg/dl in 42% of subjects&#x000a0;within 6 months.<xref ref-type="bibr" rid="article-22376.r164">[164]</xref>&#x000a0;During&#x000a0;the initial&#x000a0;6 months of pegloticase therapy, all patients should receive gout flare prophylaxis.</p>
        <p>Due to the risk of severe hemolytic anemia, pegloticase is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Acute gout flares are&#x000a0;observed in 80% of patients during the first few months of pegloticase therapy, even with prophylactic measures in place. Moderate infusion reactions like flushing, urticaria, and hypotension are expected, with 2% of patients experiencing severe reactions like anaphylaxis. Some reactions, such as severe muscle pain and cramping, occur due to unknown mechanisms. Efforts&#x000a0;to reduce the immunogenicity of pegloticase with concomitant use of methotrexate or mycophenolate mofetil&#x000a0;have been effective, although infusion reactions remain&#x000a0;a major issue.</p>
        <p>Rasburicase, a nonpegylated recombinant uricase, has not received&#x000a0;FDA approval for gout treatment. It prevents acute uric acid nephropathy due to tumor lysis syndrome in patients with high-risk leukemia and lymphoma.</p>
        <p>
<bold>Other Drugs With an Effect on Serum Uric Acid</bold>
</p>
        <p>Several drugs used to treat&#x000a0;conditions&#x000a0;like hypertension, type 2 DM, and&#x000a0;HLD can affect the serum uric acid (see <bold>Table.&#x000a0;</bold>Urate-Lowering Drugs and Mechanisms and <bold>Table.&#x000a0;</bold>Urate-Increasing Drugs and Mechanisms).<xref ref-type="bibr" rid="article-22376.r165">[165]</xref>&#x000a0;The sodium-glucose cotransporter-2 inhibitors (SGLT2i) are&#x000a0;particularly&#x000a0;noteworthy. Studies&#x000a0;have demonstrated their effectiveness&#x000a0;in lowering serum uric acid levels.<xref ref-type="bibr" rid="article-22376.r166">[166]</xref>&#x000a0;In an investigation&#x000a0;on the effect of empagliflozin therapy on heart failure, significant interactions&#x000a0;were observed between empagliflozin treatment and baseline&#x000a0;serum uric acid levels, affecting cardiovascular and all-cause mortality.<xref ref-type="bibr" rid="article-22376.r167">[167]</xref>&#x000a0;Additionally,&#x000a0;SGLT2 inhibitors have been shown to reduce the risk of developing incident gout and acute flares of gouty arthritis.<xref ref-type="bibr" rid="article-22376.r167">[167]</xref><xref ref-type="bibr" rid="article-22376.r168">[168]</xref>&#x000a0;</p>
        <table-wrap id="article-22376.table8" position="float" orientation="portrait">
          <caption>
            <title>Table 8.&#x000a0;Urate-Lowering Drugs and Mechanisms&#x000a0;[165]</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 249.352px;" rowspan="1" colspan="1">Drug class</td>
                <td style="width: 221.648px;" rowspan="1" colspan="1">Drug</td>
                <td style="width: 315px;" rowspan="1" colspan="1">Mechanism</td>
              </tr>
              <tr>
                <td style="width: 249.352px;" rowspan="1" colspan="1">Antihypertensive</td>
                <td style="width: 221.648px;" rowspan="1" colspan="1">
<p>Losartan</p>
<p>CCBs</p>
</td>
                <td style="width: 315px;" rowspan="1" colspan="1">
<p>Increases excretion, decreases URAT1</p>
<p>Various</p>
</td>
              </tr>
              <tr>
                <td style="width: 249.352px;" rowspan="1" colspan="1">
<p>Anti-inflammatory</p>
<p>Immunosuppressive</p>
</td>
                <td style="width: 221.648px;" rowspan="1" colspan="1">
<p>High dose aspirin</p>
<p>Leflunomide</p>
</td>
                <td style="width: 315px;" rowspan="1" colspan="1">
<p>Biphasic effect on resorption</p>
<p>Increases excretion</p>
</td>
              </tr>
              <tr>
                <td style="width: 249.352px;" rowspan="1" colspan="1">Lipid-lowering</td>
                <td style="width: 221.648px;" rowspan="1" colspan="1">
<p>Statins</p>
<p>Fenofibrate</p>
</td>
                <td style="width: 315px;" rowspan="1" colspan="1">
<p>Unknown</p>
<p>Increases excretion</p>
</td>
              </tr>
              <tr>
                <td style="width: 249.352px;" rowspan="1" colspan="1">Metabolism modulator</td>
                <td style="width: 221.648px;" rowspan="1" colspan="1">SGLT2 inhibitors</td>
                <td style="width: 315px;" rowspan="1" colspan="1">Increases excretion, GLUT9</td>
              </tr>
              <tr>
                <td style="width: 249.352px;" rowspan="1" colspan="1">Sex hormone</td>
                <td style="width: 221.648px;" rowspan="1" colspan="1">Estrogen</td>
                <td style="width: 315px;" rowspan="1" colspan="1">Decreases resorption</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap id="article-22376.table9" position="float" orientation="portrait">
          <caption>
            <title>Table 9.&#x000a0;Urate-Increasing Drugs and Mechanisms&#x000a0;[165]</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 235.609px;" rowspan="1" colspan="1">Drug class</td>
                <td style="width: 223.391px;" rowspan="1" colspan="1">Drug</td>
                <td style="width: 330px;" rowspan="1" colspan="1">Mechanism</td>
              </tr>
              <tr>
                <td style="width: 235.609px;" rowspan="1" colspan="1">Diuretic</td>
                <td style="width: 223.391px;" rowspan="1" colspan="1">Loop diuretics</td>
                <td style="width: 330px;" rowspan="1" colspan="1">
<p>Decreases excretion, decreases MRP4</p>
<p>Increases resorption, increases URAT1</p>
</td>
              </tr>
              <tr>
                <td style="width: 235.609px;" rowspan="1" colspan="1">Other antihypertensive</td>
                <td style="width: 223.391px;" rowspan="1" colspan="1">
<p>Thiazide diuretics</p>
<p>Beta-blockers</p>
</td>
                <td style="width: 330px;" rowspan="1" colspan="1">
<p>Decreases excretion, decreases MRP4</p>
<p>Increases resorption, increases URAT1</p>
<p>Unknown</p>
</td>
              </tr>
              <tr>
                <td style="width: 235.609px;" rowspan="1" colspan="1">Antituberculosis drug</td>
                <td style="width: 223.391px;" rowspan="1" colspan="1">
<p>Pyrazinamide</p>
<p>Ethambutol</p>
</td>
                <td style="width: 330px;" rowspan="1" colspan="1">
<p>Increase resorption, increases URAT1</p>
<p>Decreased renal clearance</p>
</td>
              </tr>
              <tr>
                <td style="width: 235.609px;" rowspan="1" colspan="1">
<p>Anti-inflammatory</p>
<p>Immunosuppressive</p>
</td>
                <td style="width: 223.391px;" rowspan="1" colspan="1">
<p>Low-dose aspirin</p>
<p>Calcineurin inhibitors</p>
</td>
                <td style="width: 330px;" rowspan="1" colspan="1">
<p>Biphasic effect on resportion</p>
<p>Decreases renal clearance</p>
</td>
              </tr>
              <tr>
                <td style="width: 235.609px;" rowspan="1" colspan="1">Metabolism modulator</td>
                <td style="width: 223.391px;" rowspan="1" colspan="1">
<p>Lactate</p>
<p>Insulin</p>
</td>
                <td style="width: 330px;" rowspan="1" colspan="1">
<p>Increases resorption, increases URAT1</p>
<p>Increases resorption, increases URAT1</p>
</td>
              </tr>
              <tr>
                <td style="width: 235.609px;" rowspan="1" colspan="1">Sex hormone</td>
                <td style="width: 223.391px;" rowspan="1" colspan="1">Testosterone</td>
                <td style="width: 330px;" rowspan="1" colspan="1">Increases resorption, increases URAT1</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-22376.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for an acute gout flare includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Calcium pyrophosphate crystal deposition disease</p>
          </list-item>
          <list-item>
            <p>Basic calcium phosphate crystal disease</p>
          </list-item>
          <list-item>
            <p>Septic arthritis (crystal arthritis and septic arthritis may coexist)&#x000a0;<xref ref-type="bibr" rid="article-22376.r92">[92]</xref></p>
          </list-item>
          <list-item>
            <p>OA</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis</p>
          </list-item>
          <list-item>
            <p>Cellulitis</p>
          </list-item>
          <list-item>
            <p>Trauma</p>
          </list-item>
        </list>
        <p>The differential diagnosis for tophaceous gout includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dactylitis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Osteomyelitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22376.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of gout&#x000a0;varies based on&#x000a0;the individual comorbidities. Patients with cardiovascular comorbidities tend to have higher mortality rates. Most patients can lead an everyday&#x000a0;life with mild sequelae with proper treatment.&#x000a0;Those experiencing symptoms early in life often present with more severe disease. Without lifestyle modifications, recurrent flare-ups are common.&#x000a0;</p>
      </sec>
      <sec id="article-22376.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of gout are diverse and may encompass various systemic issues, including the following:<xref ref-type="bibr" rid="article-22376.r169">[169]</xref></p>
        <p>
<bold>Skeletal Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tophi</p>
          </list-item>
          <list-item>
            <p>Joint deformity</p>
          </list-item>
          <list-item>
            <p>OA</p>
          </list-item>
          <list-item>
            <p>Bone loss</p>
          </list-item>
        </list>
        <p>
<bold>Urological Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Urate nephropathy</p>
          </list-item>
          <list-item>
            <p>Nephrolithiasis</p>
          </list-item>
        </list>
        <p>
<bold>Ocular Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Conjunctivitis</p>
          </list-item>
          <list-item>
            <p>Uveitis</p>
          </list-item>
          <list-item>
            <p>Scleritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22376.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about lifestyle modifications and strategies to reduce the risk of gout flares and the condition's progression.&#x000a0;Important&#x000a0;points&#x000a0;to&#x000a0;discuss with patients include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lifestyle changes are encouraged for patients with gout, including weight loss, limiting alcohol consumption, and avoiding certain foods. While these changes can significantly complement medical therapy, they might not always suffice to manage or reverse gout effectively.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Weight gain and increased adiposity are risk factors for gout. In individuals with established gout who are overweight, weight loss&#x000a0;is likely&#x000a0;beneficial,&#x000a0;leading to reductions in serum urate and alleviation of gout symptoms.<xref ref-type="bibr" rid="article-22376.r170">[170]</xref><xref ref-type="bibr" rid="article-22376.r171">[171]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The optimal diet composition for managing gout&#x000a0;includes&#x000a0;adequate protein intake, especially from plant sources and low-fat dairy sources, while reducing consumption of&#x000a0;animal sources&#x000a0;high in&#x000a0;purine, such as shellfish or red meat. Decreasing saturated fat intake and replacing simple sugars with complex carbohydrates is essential.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>It is advisable to avoid or&#x000a0;significantly&#x000a0;reduce the&#x000a0;consumption of sugar-sweetened juices, alcoholic beverages, and&#x000a0;drinks containing high-fructose corn syrup.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22376.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>IL-1 is an important mediator of inflammation in gout and represents a potential therapeutic target for managing&#x000a0;gout flares.<xref ref-type="bibr" rid="article-22376.r172">[172]</xref>&#x000a0;For patients with multiple medical comorbidities or are on anticoagulation, a short-acting IL-1 inhibitor, like anakinra, can be&#x000a0;considered&#x000a0;an an alternative treatment for&#x000a0;gout flare as an alternative to the first-line therapies.</p>
      </sec>
      <sec id="article-22376.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Most patients with gout commonly have accompanying comorbidities. The prevalence of gout is higher among individuals with chronic diseases such as HTN, CKD, DM, obesity, CHF, and MI.<xref ref-type="bibr" rid="article-22376.r173">[173]</xref></p>
        <p>Gout treatment&#x000a0;necessitates&#x000a0;a collaborative approach&#x000a0;from an entire interprofessional healthcare team. The&#x000a0;healthcare professional&#x000a0;must&#x000a0;swiftly&#x000a0;identify the pathology and rule out other causes. In some cases, a rheumatology consult might be necessary. When developing pharmacological approaches, considering comorbidities&#x000a0;is essential, and monitoring their response to treatment is crucial.</p>
        <p>The pharmacist and nurse are pivotal in educating the patient&#x000a0;on medication compliance. Pharmacists should also assist the team by&#x000a0;conducting&#x000a0;medication reconciliation, verifying appropriate dosing, and&#x000a0;providing input&#x000a0;on agent selection&#x000a0;if the initial treatment proves ineffective.</p>
        <p>Dietitians should&#x000a0;encourage patients to abstain from alcohol, avoid purine-rich foods, and maintain a healthy body weight. The&#x000a0;collaborative efforts&#x000a0;of specialists, primary care providers, nurses, nurse practitioners, and dieticians are instrumental in reducing gout morbidity associated with gout. Effective communication among all team members is vital in coordinating patient education on lifestyle modifications, significantly reducing the risk and frequency of gout flare-ups.</p>
        <p>Healthcare providers, including primary care physicians, physician assistants, and nurse practitioners, should be adept at identifying classic gout symptoms and have a low threshold for referring patients for an arthrocentesis if&#x000a0;there is any&#x000a0;uncertainty about the diagnosis. Collaborating with the interprofessional team, as detailed earlier, is essential.</p>
        <p>Referral to a specialist, such as a rheumatologist, should be considered for patients with joint pain in the following situations:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Unclear etiology with hyperuricemia</p>
          </list-item>
          <list-item>
            <p>Unclear etiology with normal serum urate level</p>
          </list-item>
          <list-item>
            <p>Patients with renal impairment</p>
          </list-item>
          <list-item>
            <p>Failed trial of XOI&#x000a0;treatment</p>
          </list-item>
          <list-item>
            <p>Multiple side effects from the medications</p>
          </list-item>
          <list-item>
            <p>Refractory gout&#x000a0;<xref ref-type="bibr" rid="article-22376.r102">[102]</xref></p>
          </list-item>
        </list>
        <p>Only through an interprofessional team approach with close communication can the morbidity of gout be lowered.&#x000a0;Directing the treatment appropriately and maintaining active communication within the team is vital to achieving favorable outcomes.</p>
      </sec>
      <sec id="article-22376.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22376&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22376">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22376/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22376">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22376.s17">
        <fig id="article-22376.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Hand Radiograph, Gout Contributed by Scott Dulebohn, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gouty__destruction" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22376.s18">
        <fig id="article-22376.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Gout, [SATA] Contributed by Steve Bhmji, MS, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gout" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22376.s19">
        <fig id="article-22376.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Gout in the Ear Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eargout" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22376.s20">
        <fig id="article-22376.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Acute gout attack Image courtesy O.Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gouta" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22376.s21">
        <fig id="article-22376.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Gout Tophi Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gout__tophi__SV" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22376.s22">
        <title>References</title>
        <ref id="article-22376.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Gout.</article-title>
            <source>Ann Intern Med</source>
            <year>2016</year>
            <month>Jul</month>
            <day>05</day>
            <volume>165</volume>
            <issue>1</issue>
            <fpage>ITC1</fpage>
            <page-range>ITC1-ITC16</page-range>
            <pub-id pub-id-type="pmid">27380294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Merriman</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Stamp</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Gout.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Oct</month>
            <day>22</day>
            <volume>388</volume>
            <issue>10055</issue>
            <fpage>2039</fpage>
            <page-range>2039-2052</page-range>
            <pub-id pub-id-type="pmid">27112094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Gout.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Jan</month>
            <day>23</day>
            <volume>375</volume>
            <issue>9711</issue>
            <fpage>318</fpage>
            <page-range>318-28</page-range>
            <pub-id pub-id-type="pmid">19692116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simkin</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>A concise history of gout and hyperuricemia and their treatment.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2006</year>
            <volume>8 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S1</fpage>
            <pub-id pub-id-type="pmid">16820040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loeb</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>The influence of temperature on the solubility of monosodium urate.</article-title>
            <source>Arthritis Rheum</source>
            <year>1972</year>
            <season>Mar-Apr</season>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-92</page-range>
            <pub-id pub-id-type="pmid">5027604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nian</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Susceptibility genes of hyperuricemia and gout.</article-title>
            <source>Hereditas</source>
            <year>2022</year>
            <month>Aug</month>
            <day>04</day>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">35922835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merriman</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The genetic basis of gout.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2014</year>
            <month>May</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-90</page-range>
            <pub-id pub-id-type="pmid">24703347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Mount</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Reginato</surname>
                <given-names>AM</given-names>
              </name>
              <collab>American College of Physicians</collab>
              <collab>American Physiological Society</collab>
            </person-group>
            <article-title>Pathogenesis of gout.</article-title>
            <source>Ann Intern Med</source>
            <year>2005</year>
            <month>Oct</month>
            <day>04</day>
            <volume>143</volume>
            <issue>7</issue>
            <fpage>499</fpage>
            <page-range>499-516</page-range>
            <pub-id pub-id-type="pmid">16204163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gaucher</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.</article-title>
            <source>Mol Biol Evol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>2193</fpage>
            <page-range>2193-200</page-range>
            <pub-id pub-id-type="pmid">27352852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abhishek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roddy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Gout - a guide for the general and acute physicians.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-59</page-range>
            <pub-id pub-id-type="pmid">28148582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Asymptomatic hyperuricaemia.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1987</year>
            <month>Apr</month>
            <day>18</day>
            <volume>294</volume>
            <issue>6578</issue>
            <fpage>987</fpage>
            <page-range>987-8</page-range>
            <pub-id pub-id-type="pmid">3119013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Phipps-Green</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frampton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Merriman</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>77</volume>
            <issue>7</issue>
            <fpage>1048</fpage>
            <page-range>1048-1052</page-range>
            <pub-id pub-id-type="pmid">29463518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>EQ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?</article-title>
            <source>J Rheumatol</source>
            <year>2009</year>
            <month>May</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>1032</fpage>
            <page-range>1032-40</page-range>
            <pub-id pub-id-type="pmid">19369467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study.</article-title>
            <source>BMJ</source>
            <year>2008</year>
            <month>Feb</month>
            <day>09</day>
            <volume>336</volume>
            <issue>7639</issue>
            <fpage>309</fpage>
            <page-range>309-12</page-range>
            <pub-id pub-id-type="pmid">18244959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Fructose-rich beverages and risk of gout in women.</article-title>
            <source>JAMA</source>
            <year>2010</year>
            <month>Nov</month>
            <day>24</day>
            <volume>304</volume>
            <issue>20</issue>
            <fpage>2270</fpage>
            <page-range>2270-8</page-range>
            <pub-id pub-id-type="pmid">21068145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyperuricaemia and gout: state of the art and future perspectives.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>10</issue>
            <fpage>1738</fpage>
            <page-range>1738-43</page-range>
            <pub-id pub-id-type="pmid">20858623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karlson</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Purine-rich foods, dairy and protein intake, and the risk of gout in men.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Mar</month>
            <day>11</day>
            <volume>350</volume>
            <issue>11</issue>
            <fpage>1093</fpage>
            <page-range>1093-103</page-range>
            <pub-id pub-id-type="pmid">15014182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juraschek</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Yokose</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Effects of Dietary Patterns on Serum Urate: Results From a Randomized Trial of the Effects of Diet on Hypertension.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>1014</fpage>
            <page-range>1014-1020</page-range>
            <pub-id pub-id-type="pmid">33615722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rai</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study.</article-title>
            <source>BMJ</source>
            <year>2017</year>
            <month>May</month>
            <day>09</day>
            <volume>357</volume>
            <fpage>j1794</fpage>
            <pub-id pub-id-type="pmid">28487277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Charleston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Norkus</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1843</fpage>
            <page-range>1843-7</page-range>
            <pub-id pub-id-type="pmid">15934094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ascherio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Vitamin C intake and serum uric acid concentration in men.</article-title>
            <source>J Rheumatol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1853</fpage>
            <page-range>1853-8</page-range>
            <pub-id pub-id-type="pmid">18464304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juraschek</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>63</volume>
            <issue>9</issue>
            <fpage>1295</fpage>
            <page-range>1295-306</page-range>
            <pub-id pub-id-type="pmid">21671418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Vitamin C intake and the risk of gout in men: a prospective study.</article-title>
            <source>Arch Intern Med</source>
            <year>2009</year>
            <month>Mar</month>
            <day>09</day>
            <volume>169</volume>
            <issue>5</issue>
            <fpage>502</fpage>
            <page-range>502-7</page-range>
            <pub-id pub-id-type="pmid">19273781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juraschek</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Gaziano</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gomelskaya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bubes</surname>
                <given-names>VY</given-names>
              </name>
              <name>
                <surname>Buring</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Shmerling</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Sesso</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Effects of vitamin C supplementation on gout risk: results from the Physicians' Health Study II trial.</article-title>
            <source>Am J Clin Nutr</source>
            <year>2022</year>
            <month>Sep</month>
            <day>02</day>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>812</fpage>
            <page-range>812-819</page-range>
            <pub-id pub-id-type="pmid">35575611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Spinozzi</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Prior</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hess-Pierce</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kader</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Consumption of cherries lowers plasma urate in healthy women.</article-title>
            <source>J Nutr</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>133</volume>
            <issue>6</issue>
            <fpage>1826</fpage>
            <page-range>1826-9</page-range>
            <pub-id pub-id-type="pmid">12771324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Cherry consumption and decreased risk of recurrent gout attacks.</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>12</issue>
            <fpage>4004</fpage>
            <page-range>4004-11</page-range>
            <pub-id pub-id-type="pmid">23023818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glynn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Campion</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Silbert</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Trends in serum uric acid levels 1961--1980.</article-title>
            <source>Arthritis Rheum</source>
            <year>1983</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-93</page-range>
            <pub-id pub-id-type="pmid">6824508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takiue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hosoyamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The effect of female hormones upon urate transport systems in the mouse kidney.</article-title>
            <source>Nucleosides Nucleotides Nucleic Acids</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-9</page-range>
            <pub-id pub-id-type="pmid">21360409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rho</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of uric acid and fructose.</article-title>
            <source>Semin Nephrol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>410</fpage>
            <page-range>410-9</page-range>
            <pub-id pub-id-type="pmid">22000647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hak</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2008</year>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>R116</fpage>
            <pub-id pub-id-type="pmid">18822120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arromdee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Michet</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>O'Fallon</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of gout: is the incidence rising?</article-title>
            <source>J Rheumatol</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>2403</fpage>
            <page-range>2403-6</page-range>
            <pub-id pub-id-type="pmid">12415600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of crystal arthropathy.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2006</year>
            <month>May</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-73, v</page-range>
            <pub-id pub-id-type="pmid">16716879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ragab</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elshahaly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Gout: An old disease in new perspective - A review.</article-title>
            <source>J Adv Res</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>495</fpage>
            <page-range>495-511</page-range>
            <pub-id pub-id-type="pmid">28748116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawrence</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Felson</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Helmick</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deyo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kremers</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>F</given-names>
              </name>
              <collab>National Arthritis Data Workgroup</collab>
            </person-group>
            <article-title>Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.</article-title>
            <source>Arthritis Rheum</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-35</page-range>
            <pub-id pub-id-type="pmid">18163497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pandya</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.</article-title>
            <source>Arthritis Rheum</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>3136</fpage>
            <page-range>3136-41</page-range>
            <pub-id pub-id-type="pmid">21800283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramer</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-42</page-range>
            <pub-id pub-id-type="pmid">12087559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormick</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yokose</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Sheehy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Merriman</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Racial and Sex Disparities in Gout Prevalence Among US Adults.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Aug</month>
            <day>01</day>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>e2226804</fpage>
            <pub-id pub-id-type="pmid">35969396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elfishawi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Zleik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kvrgic</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Michet</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Bongartz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years.</article-title>
            <source>J Rheumatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>574</fpage>
            <page-range>574-579</page-range>
            <pub-id pub-id-type="pmid">29247151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Grainge</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>661</fpage>
            <page-range>661-7</page-range>
            <pub-id pub-id-type="pmid">24431399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Newson</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Cardoso</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Incident gout and weight change patterns: a retrospective cohort study of US adults.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2021</year>
            <month>Mar</month>
            <day>02</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <pub-id pub-id-type="pmid">33653403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Relationship Between Changing Body Mass Index and Serum Uric Acid Alteration Among Clinically Apparently Healthy Korean Men.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>8</issue>
            <fpage>1277</fpage>
            <page-range>1277-1286</page-range>
            <pub-id pub-id-type="pmid">33544980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Modifiable risk factors and incidence of gout: Estimation of population attributable fraction in the US.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>55</volume>
            <fpage>152040</fpage>
            <pub-id pub-id-type="pmid">35679791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annemans</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Spaepen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaskin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonnemaire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malier</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>67</volume>
            <issue>7</issue>
            <fpage>960</fpage>
            <page-range>960-6</page-range>
            <pub-id pub-id-type="pmid">17981913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Grainge</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comorbidities in patients with gout prior to and following diagnosis: case-control study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>210</fpage>
            <page-range>210-7</page-range>
            <pub-id pub-id-type="pmid">25398375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnan</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>12</issue>
            <fpage>3271</fpage>
            <page-range>3271-8</page-range>
            <pub-id pub-id-type="pmid">23982888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moon</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Risks in Korean Patients with Gout: Analysis Using a National Health Insurance Service Database.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>11</day>
            <volume>11</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">35456221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cipolletta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tata</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Nakafero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mamas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Abhishek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Aug</month>
            <day>02</day>
            <volume>328</volume>
            <issue>5</issue>
            <fpage>440</fpage>
            <page-range>440-450</page-range>
            <pub-id pub-id-type="pmid">35916846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Disveld</surname>
                <given-names>IJM</given-names>
              </name>
              <name>
                <surname>Zoakman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TLTA</given-names>
              </name>
              <name>
                <surname>Rongen</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kienhorst</surname>
                <given-names>LBE</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>HJEM</given-names>
              </name>
              <name>
                <surname>Fransen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study.</article-title>
            <source>Clin Rheumatol</source>
            <year>2019</year>
            <month>May</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>1385</fpage>
            <page-range>1385-1391</page-range>
            <pub-id pub-id-type="pmid">30929152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioachimescu</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hoar</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Hazen</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hoogwerf</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>623</fpage>
            <page-range>623-30</page-range>
            <pub-id pub-id-type="pmid">18240236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vargas-Santos</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>da Rocha Castelar-Pinheiro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapetanovic</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Turkiewicz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Non-Cardiovascular-Related Deaths.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>11</issue>
            <fpage>1935</fpage>
            <page-range>1935-1942</page-range>
            <pub-id pub-id-type="pmid">31169353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HY</given-names>
              </name>
            </person-group>
            <article-title>Gout and the risk of dementia: a nationwide population-based cohort study.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2015</year>
            <month>May</month>
            <day>28</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <pub-id pub-id-type="pmid">26018424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Association Between Gout and Dementia in the Elderly: A Nationwide Population-Based Cohort Study.</article-title>
            <source>Am J Geriatr Psychiatry</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>12</issue>
            <fpage>1177</fpage>
            <page-range>1177-1185</page-range>
            <pub-id pub-id-type="pmid">33593591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>QP</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Risk of dementia in gout and hyperuricaemia: a meta-analysis of cohort studies.</article-title>
            <source>BMJ Open</source>
            <year>2021</year>
            <month>Jun</month>
            <day>22</day>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>e041680</fpage>
            <pub-id pub-id-type="pmid">34158290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eom</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Impact of Clinical Association Between Gout and Dementia: A Nationwide Population-Based Cohort Study in Korea.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2023</year>
            <month>May</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>1088</fpage>
            <page-range>1088-1094</page-range>
            <pub-id pub-id-type="pmid">35604886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Ascherio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;n</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>547</fpage>
            <page-range>547-51</page-range>
            <pub-id pub-id-type="pmid">25739830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Gout and dementia in the elderly: a cohort study of Medicare claims.</article-title>
            <source>BMC Geriatr</source>
            <year>2018</year>
            <month>Nov</month>
            <day>14</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>281</fpage>
            <pub-id pub-id-type="pmid">30428833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latourte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soumar&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Debette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>328</fpage>
            <page-range>328-335</page-range>
            <pub-id pub-id-type="pmid">28754803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Logroscino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;n</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Gout and risk of Parkinson disease: a prospective study.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Oct</month>
            <day>23</day>
            <volume>69</volume>
            <issue>17</issue>
            <fpage>1696</fpage>
            <page-range>1696-700</page-range>
            <pub-id pub-id-type="pmid">17954784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Vera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rankin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kopec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Gout and the risk of Parkinson's disease: a cohort study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2008</year>
            <month>Nov</month>
            <day>15</day>
            <volume>59</volume>
            <issue>11</issue>
            <fpage>1549</fpage>
            <page-range>1549-54</page-range>
            <pub-id pub-id-type="pmid">18975349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pou</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Orfila</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pagonabarraga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrer-Moret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corominas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Diaz-Torne</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Risk of Parkinson's disease in a gout Mediterranean population: A case-control study.</article-title>
            <source>Joint Bone Spine</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>105402</fpage>
            <pub-id pub-id-type="pmid">35504516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fazlollahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zahmatyar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alizadeh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Noori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jafari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nejadghaderi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sullman</surname>
                <given-names>MJM</given-names>
              </name>
              <name>
                <surname>Gharagozli</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolahi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Safiri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.</article-title>
            <source>BMC Neurol</source>
            <year>2022</year>
            <month>Oct</month>
            <day>11</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>383</fpage>
            <pub-id pub-id-type="pmid">36221048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Risk of Parkinson's disease following gout: a population-based retrospective cohort study in Taiwan.</article-title>
            <source>BMC Neurol</source>
            <year>2020</year>
            <month>Sep</month>
            <day>08</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>338</fpage>
            <pub-id pub-id-type="pmid">32900384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Gout and the risk of Parkinson's disease in older adults: a study of U.S. Medicare data.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>05</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <pub-id pub-id-type="pmid">30611222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bursill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abhishek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Vargas-Santos</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gaffo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tausche</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Reginato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scir&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pineda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Durme</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Biernat-Kaluza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roddy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Becce</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sivera</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schett</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Filippou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>da Rocha Castelar Pinheiro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ea</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Tupinamb&#x000e1;</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Mackay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>ODell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez Mellado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jacobsson</surname>
                <given-names>LTH</given-names>
              </name>
              <name>
                <surname>Joosten</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Stamp</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuwabara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dehlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hershfield</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Slot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ottaviani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>MacMullan</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Gancheva</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Te Kampe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Keenan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Merriman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pascart</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kl&#x000fc;ck</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Louthrenoo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>78</volume>
            <issue>11</issue>
            <fpage>1592</fpage>
            <page-range>1592-1600</page-range>
            <pub-id pub-id-type="pmid">31501138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bursill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kuwabara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merriman</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pineda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Louthrenoo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vargas-Santos</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Roddy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pascart</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Tausche</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Vazquez-Mellado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>da Rocha Castelar-Pinheiro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Burgos-Vargas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Slot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Keenan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Scire</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Biernat-Kaluza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dehlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stamp</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Sivera</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reginato</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jacobsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ea</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Hershfield</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Czegley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>427</fpage>
            <page-range>427-434</page-range>
            <pub-id pub-id-type="pmid">29799677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gosling</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gaffo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abhishek</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gout.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>May</month>
            <day>15</day>
            <volume>397</volume>
            <issue>10287</issue>
            <fpage>1843</fpage>
            <page-range>1843-1855</page-range>
            <pub-id pub-id-type="pmid">33798500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steiger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Molecular Pathophysiology of Gout.</article-title>
            <source>Trends Mol Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>756</fpage>
            <page-range>756-768</page-range>
            <pub-id pub-id-type="pmid">28732688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chhana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Factors influencing the crystallization of monosodium urate: a systematic literature review.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2015</year>
            <month>Oct</month>
            <day>14</day>
            <volume>16</volume>
            <fpage>296</fpage>
            <pub-id pub-id-type="pmid">26467213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Addadi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sivera</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of crystal formation in gout-a structural approach.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>725</fpage>
            <page-range>725-30</page-range>
            <pub-id pub-id-type="pmid">26369610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franklin</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Mangan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Latz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Crystal Formation in Inflammation.</article-title>
            <source>Annu Rev Immunol</source>
            <year>2016</year>
            <month>May</month>
            <day>20</day>
            <volume>34</volume>
            <fpage>173</fpage>
            <page-range>173-202</page-range>
            <pub-id pub-id-type="pmid">26772211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ginsberg</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kozin</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of cellular interaction with monosodium urate crystals. IgG-dependent and IgG-independent platelet stimulation by urate crystals.</article-title>
            <source>Arthritis Rheum</source>
            <year>1978</year>
            <season>Nov-Dec</season>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>896</fpage>
            <page-range>896-903</page-range>
            <pub-id pub-id-type="pmid">737013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giclas</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Immunoglobulin G independent activation of the classical complement pathway by monosodium urate crystals.</article-title>
            <source>J Clin Invest</source>
            <year>1979</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <page-range>759-64</page-range>
            <pub-id pub-id-type="pmid">438335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fields</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Ghebrehiwet</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Activation of the alternative pathway of complement by monosodium urate crystals.</article-title>
            <source>Clin Immunol Immunopathol</source>
            <year>1983</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-57</page-range>
            <pub-id pub-id-type="pmid">6872344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>So</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Martinon</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Inflammation in gout: mechanisms and therapeutic targets.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>639</fpage>
            <page-range>639-647</page-range>
            <pub-id pub-id-type="pmid">28959043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>The Immunological Basis in the Pathogenesis of Gout.</article-title>
            <source>Iran J Immunol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-98</page-range>
            <pub-id pub-id-type="pmid">28630380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout.</article-title>
            <source>Front Pharmacol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>861399</fpage>
            <pub-id pub-id-type="pmid">35370689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chhana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Structural joint damage in gout.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2014</year>
            <month>May</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>291</fpage>
            <page-range>291-309</page-range>
            <pub-id pub-id-type="pmid">24703348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gamble</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McQueen</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>68</volume>
            <issue>8</issue>
            <fpage>1290</fpage>
            <page-range>1290-5</page-range>
            <pub-id pub-id-type="pmid">18708415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nicolson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Callon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haskard</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>McQueen</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Cornish</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells.</article-title>
            <source>Arthritis Rheum</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>1854</fpage>
            <page-range>1854-65</page-range>
            <pub-id pub-id-type="pmid">18512794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MCCARTY</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>HOLLANDER</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Identification of urate crystals in gouty synovial fluid.</article-title>
            <source>Ann Intern Med</source>
            <year>1961</year>
            <month>Mar</month>
            <volume>54</volume>
            <fpage>452</fpage>
            <page-range>452-60</page-range>
            <pub-id pub-id-type="pmid">13773775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Towiwat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chhana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The anatomical pathology of gout: a systematic literature review.</article-title>
            <source>BMC Musculoskelet Disord</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>140</fpage>
            <pub-id pub-id-type="pmid">30935368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Franck</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Bress</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Acute polyarticular gout.</article-title>
            <source>Am J Med</source>
            <year>1974</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-9</page-range>
            <pub-id pub-id-type="pmid">4825606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komarla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Spinal gout presenting as acute low back pain.</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>2660</fpage>
            <pub-id pub-id-type="pmid">23818092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lumezanu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Konatalapalli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Axial (spinal) gout.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-4</page-range>
            <pub-id pub-id-type="pmid">22318623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Y&#x000fc;</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Secondary gout associated with myeloproliferative diseases.</article-title>
            <source>Arthritis Rheum</source>
            <year>1965</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>765</fpage>
            <page-range>765-71</page-range>
            <pub-id pub-id-type="pmid">5216775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Rocher</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>McQuillan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schmaltz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palella</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine-induced hyperuricemia and gout.</article-title>
            <source>N Engl J Med</source>
            <year>1989</year>
            <month>Aug</month>
            <day>03</day>
            <volume>321</volume>
            <issue>5</issue>
            <fpage>287</fpage>
            <page-range>287-92</page-range>
            <pub-id pub-id-type="pmid">2664517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Nocturnal risk of gout attacks.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>555</fpage>
            <page-range>555-62</page-range>
            <pub-id pub-id-type="pmid">25504842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rakieh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Conaghan</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of gout in primary care.</article-title>
            <source>Practitioner</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>255</volume>
            <issue>1746</issue>
            <fpage>17</fpage>
            <page-range>17-20, 2-3</page-range>
            <pub-id pub-id-type="pmid">22272526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Flueckiger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Corrigan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Conn</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Polyarticular Gout Flare Masquerading as Sepsis.</article-title>
            <source>Am J Med</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>128</volume>
            <issue>7</issue>
            <fpage>e11</fpage>
            <page-range>e11-2</page-range>
            <pub-id pub-id-type="pmid">25614957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Batlle-Gualda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vela</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Synovial fluid analysis for diagnosis of intercritical gout.</article-title>
            <source>Ann Intern Med</source>
            <year>1999</year>
            <month>Nov</month>
            <day>16</day>
            <volume>131</volume>
            <issue>10</issue>
            <fpage>756</fpage>
            <page-range>756-9</page-range>
            <pub-id pub-id-type="pmid">10577299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coakley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kingsley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bradish</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weston</surname>
                <given-names>V</given-names>
              </name>
              <collab>British Society for Rheumatology Standards, Guidelines and Audit Working Group</collab>
            </person-group>
            <article-title>BSR &#x00026; BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1039</fpage>
            <page-range>1039-41</page-range>
            <pub-id pub-id-type="pmid">16829534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Concomitant septic and gouty arthritis--an analysis of 30 cases.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>9</issue>
            <fpage>1062</fpage>
            <page-range>1062-6</page-range>
            <pub-id pub-id-type="pmid">12730521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivera</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quilis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Gout: Diagnosis and treatment.</article-title>
            <source>Med Clin (Barc)</source>
            <year>2017</year>
            <month>Mar</month>
            <day>22</day>
            <volume>148</volume>
            <issue>6</issue>
            <fpage>271</fpage>
            <page-range>271-276</page-range>
            <pub-id pub-id-type="pmid">27931865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huppertz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Diekhoff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout.</article-title>
            <source>Rheumatol Int</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>763</fpage>
            <page-range>763-71</page-range>
            <pub-id pub-id-type="pmid">24619560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogdie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Weatherall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fransen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Imaging modalities for the classification of gout: systematic literature review and meta-analysis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>1868</fpage>
            <page-range>1868-74</page-range>
            <pub-id pub-id-type="pmid">24915980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garner</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Wessell</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Current status of ultrasound and dual-energy computed tomography in the evaluation of gout.</article-title>
            <source>Rheumatol Int</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>1339</fpage>
            <page-range>1339-1344</page-range>
            <pub-id pub-id-type="pmid">29721694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Role of Advanced Imaging in Gout Management.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>811323</fpage>
            <pub-id pub-id-type="pmid">35095904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic accuracy of ultrasound in patients with gout: A meta-analysis.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>703</fpage>
            <page-range>703-709</page-range>
            <pub-id pub-id-type="pmid">29054295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barskova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Becce</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda-Sanabria</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coyfish</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guillo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pimentao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Punzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pywell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tausche</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zavada</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tubach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2016 updated EULAR evidence-based recommendations for the management of gout.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-42</page-range>
            <pub-id pub-id-type="pmid">27457514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abeles</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Libbey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mount</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Danve</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lenert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehra</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>TSK</given-names>
              </name>
              <name>
                <surname>Toprover</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2020 American College of Rheumatology Guideline for the Management of Gout.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>744</fpage>
            <page-range>744-760</page-range>
            <pub-id pub-id-type="pmid">32391934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Detry</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Beutler</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rull</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Local ice therapy during bouts of acute gouty arthritis.</article-title>
            <source>J Rheumatol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>331</fpage>
            <page-range>331-4</page-range>
            <pub-id pub-id-type="pmid">11838852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Merill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaldas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niyyar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yarows</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roessler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Mandell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
              <collab>American College of Rheumatology</collab>
            </person-group>
            <article-title>2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>64</volume>
            <issue>10</issue>
            <fpage>1431</fpage>
            <page-range>1431-46</page-range>
            <pub-id pub-id-type="pmid">23024028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barskova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Conaghan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gerster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leeb</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Netter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pignone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piment&#x000e3;o</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Punzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roddy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zimmermann-G&#x000f2;rska</surname>
                <given-names>I</given-names>
              </name>
              <collab>EULAR Standing Committee for International Clinical Studies Including Therapeutics</collab>
            </person-group>
            <article-title>EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).</article-title>
            <source>Ann Rheum Dis</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>1312</fpage>
            <page-range>1312-24</page-range>
            <pub-id pub-id-type="pmid">16707532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barskova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Conaghan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gerster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leeb</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Netter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pignone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piment&#x000e3;o</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Punzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roddy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uhlig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zimmermann-G&#x000f2;rska</surname>
                <given-names>I</given-names>
              </name>
              <collab>EULAR Standing Committee for International Clinical Studies Including Therapeutics</collab>
            </person-group>
            <article-title>EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).</article-title>
            <source>Ann Rheum Dis</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>1301</fpage>
            <page-range>1301-11</page-range>
            <pub-id pub-id-type="pmid">16707533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>YU</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>GUTMAN</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.</article-title>
            <source>J Clin Invest</source>
            <year>1959</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>1298</fpage>
            <page-range>1298-315</page-range>
            <pub-id pub-id-type="pmid">13673086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>YUE</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>DAYTON</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>GUTMAN</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS.</article-title>
            <source>J Clin Invest</source>
            <year>1963</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>1330</fpage>
            <page-range>1330-9</page-range>
            <pub-id pub-id-type="pmid">14060403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caspi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lubart</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Graff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Habot</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yaron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients.</article-title>
            <source>Arthritis Rheum</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-8</page-range>
            <pub-id pub-id-type="pmid">10643705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lubart</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leibovitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iaina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caspi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Renal effects of low dose aspirin in elderly patients.</article-title>
            <source>Isr Med Assoc J</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>679</fpage>
            <page-range>679-82</page-range>
            <pub-id pub-id-type="pmid">17125112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>YC</given-names>
              </name>
            </person-group>
            <article-title>Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout.</article-title>
            <source>Int J Clin Pract</source>
            <year>2014</year>
            <month>May</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>633</fpage>
            <page-range>633-8</page-range>
            <pub-id pub-id-type="pmid">24472084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alloway</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hoogland</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Nashel</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis.</article-title>
            <source>J Rheumatol</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-3</page-range>
            <pub-id pub-id-type="pmid">8441139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rainer</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial.</article-title>
            <source>Ann Intern Med</source>
            <year>2016</year>
            <month>Apr</month>
            <day>05</day>
            <volume>164</volume>
            <issue>7</issue>
            <fpage>464</fpage>
            <page-range>464-71</page-range>
            <pub-id pub-id-type="pmid">26903390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Oral prednisolone versus non-steroidal anti-inflammatory drugs in the treatment of acute gout: a meta-analysis of randomized controlled trials.</article-title>
            <source>Inflammopharmacology</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>717</fpage>
            <page-range>717-723</page-range>
            <pub-id pub-id-type="pmid">29357007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qasim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2021</year>
            <month>May</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>755</fpage>
            <page-range>755-764</page-range>
            <pub-id pub-id-type="pmid">32741131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imazio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nidorf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Colchicine and the heart.</article-title>
            <source>Eur Heart J</source>
            <year>2021</year>
            <month>Jul</month>
            <day>21</day>
            <volume>42</volume>
            <issue>28</issue>
            <fpage>2745</fpage>
            <page-range>2745-2760</page-range>
            <pub-id pub-id-type="pmid">33961006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kook</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Crockett</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>1060</fpage>
            <page-range>1060-8</page-range>
            <pub-id pub-id-type="pmid">20131255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <article-title>Colchicine and other drugs for gout.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2009</year>
            <month>Nov</month>
            <day>30</day>
            <volume>51</volume>
            <issue>1326</issue>
            <fpage>93</fpage>
            <page-range>93-4</page-range>
            <pub-id pub-id-type="pmid">20224523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Billups</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Delate</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Canty</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Rawlings</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Assessment of the association between colchicine therapy and serious adverse events.</article-title>
            <source>Pharmacotherapy</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>11</issue>
            <fpage>974</fpage>
            <page-range>974-80</page-range>
            <pub-id pub-id-type="pmid">23019065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Colchicine update: 2008.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>411</fpage>
            <page-range>411-9</page-range>
            <pub-id pub-id-type="pmid">18973929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurup</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Galougahi</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Figtree</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Role of Colchicine in Atherosclerotic Cardiovascular Disease.</article-title>
            <source>Heart Lung Circ</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>795</fpage>
            <page-range>795-806</page-range>
            <pub-id pub-id-type="pmid">33461916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deftereos</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Beerkens</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giannopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vrachatis</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Giotaki</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Siasos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nicolas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arnott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tardif</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kovacic</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dangas</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Colchicine in Cardiovascular Disease: In-Depth Review.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>Jan</month>
            <day>04</day>
            <volume>145</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-78</page-range>
            <pub-id pub-id-type="pmid">34965168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Zak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>75</volume>
            <issue>9</issue>
            <fpage>1674</fpage>
            <page-range>1674-9</page-range>
            <pub-id pub-id-type="pmid">26582823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tardif</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kouz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gamra</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kiwan</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Send&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ostadal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Angoulvant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gr&#x000e9;goire</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lavoie</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Rhainds</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blondeau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Orfanos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L'Allier</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Guertin</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Roubille</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Dec</month>
            <day>26</day>
            <volume>381</volume>
            <issue>26</issue>
            <fpage>2497</fpage>
            <page-range>2497-2505</page-range>
            <pub-id pub-id-type="pmid">31733140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulus</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Schlosstein</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Klinenberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bluestone</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients.</article-title>
            <source>Arthritis Rheum</source>
            <year>1974</year>
            <season>Sep-Oct</season>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>609</fpage>
            <page-range>609-14</page-range>
            <pub-id pub-id-type="pmid">4606955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borstad</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Scroggie</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Alloway</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.</article-title>
            <source>J Rheumatol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>2429</fpage>
            <page-range>2429-32</page-range>
            <pub-id pub-id-type="pmid">15570646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Latourte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prophylaxis for acute gout flares after initiation of urate-lowering therapy.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>1920</fpage>
            <page-range>1920-6</page-range>
            <pub-id pub-id-type="pmid">24758886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liew</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis.</article-title>
            <source>J Rheumatol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>1345</fpage>
            <page-range>1345-1349</page-range>
            <pub-id pub-id-type="pmid">30647192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Keenan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Ohlman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Osterling Koskinen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sparve</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000c5;kerblad</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wik&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>8</issue>
            <fpage>1533</fpage>
            <page-range>1533-1542</page-range>
            <pub-id pub-id-type="pmid">33605029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Meulemeester</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pikhlak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Y&#x000fc;cel</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arulmani</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sallstig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>3064</fpage>
            <page-range>3064-76</page-range>
            <pub-id pub-id-type="pmid">20533546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alten</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gimona</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krammer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>11</issue>
            <fpage>1839</fpage>
            <page-range>1839-48</page-range>
            <pub-id pub-id-type="pmid">22586173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiltz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bardin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cohen Solal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>da Rocha Castelar-Pinheiro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vazquez Mellado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weisman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Westhoff</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treat-to-target (T2T) recommendations for gout.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>632</fpage>
            <page-range>632-638</page-range>
            <pub-id pub-id-type="pmid">27658678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r131">
          <label>131</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Mecchella</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kerin</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Mackenzie</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial.</article-title>
            <source>Am J Med</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>125</volume>
            <issue>11</issue>
            <fpage>1126</fpage>
            <page-range>1126-1134.e7</page-range>
            <pub-id pub-id-type="pmid">23098865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collamer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Higgs</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Does starting allopurinol prolong acute treated gout? A randomized clinical trial.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>120</fpage>
            <page-range>120-5</page-range>
            <pub-id pub-id-type="pmid">25807090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>60</volume>
            <issue>9</issue>
            <fpage>4199</fpage>
            <page-range>4199-4204</page-range>
            <pub-id pub-id-type="pmid">33404656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hung</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Fann</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YT</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2005</year>
            <month>Mar</month>
            <day>15</day>
            <volume>102</volume>
            <issue>11</issue>
            <fpage>4134</fpage>
            <page-range>4134-9</page-range>
            <pub-id pub-id-type="pmid">15743917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamp</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Dockerty</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frampton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalbeth</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <fpage>2529</fpage>
            <page-range>2529-36</page-range>
            <pub-id pub-id-type="pmid">22488501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamp</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frampton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barclay</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.</article-title>
            <source>Arthritis Rheum</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>412</fpage>
            <page-range>412-21</page-range>
            <pub-id pub-id-type="pmid">21279998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r137">
          <label>137</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarawate</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bakst</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Serum urate levels and gout flares: analysis from managed care data.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-5</page-range>
            <pub-id pub-id-type="pmid">16601538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r138">
          <label>138</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ragab</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Gilkerson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The effect of 6-mercaptopurine and allopurinol on granulopoiesis.</article-title>
            <source>Cancer Res</source>
            <year>1974</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>2246</fpage>
            <page-range>2246-9</page-range>
            <pub-id pub-id-type="pmid">4843532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r139">
          <label>139</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Wortmann</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Eustace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palo</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Streit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joseph-Ridge</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Febuxostat compared with allopurinol in patients with hyperuricemia and gout.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Dec</month>
            <day>08</day>
            <volume>353</volume>
            <issue>23</issue>
            <fpage>2450</fpage>
            <page-range>2450-61</page-range>
            <pub-id pub-id-type="pmid">16339094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r140">
          <label>140</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lademacher</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.</article-title>
            <source>J Rheumatol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1273</fpage>
            <page-range>1273-82</page-range>
            <pub-id pub-id-type="pmid">19286847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r141">
          <label>141</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Borer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gorelick</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunawardhana</surname>
                <given-names>L</given-names>
              </name>
              <collab>CARES Investigators</collab>
            </person-group>
            <article-title>Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>29</day>
            <volume>378</volume>
            <issue>13</issue>
            <fpage>1200</fpage>
            <page-range>1200-1210</page-range>
            <pub-id pub-id-type="pmid">29527974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r142">
          <label>142</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>94</volume>
            <issue>7</issue>
            <fpage>1147</fpage>
            <page-range>1147-1157</page-range>
            <pub-id pub-id-type="pmid">31272565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r143">
          <label>143</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weisshaar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Litschauer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leitner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sibinovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kossmeier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolzt</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.</article-title>
            <source>Rheumatol Int</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>9</issue>
            <fpage>1597</fpage>
            <page-range>1597-1603</page-range>
            <pub-id pub-id-type="pmid">35589988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r144">
          <label>144</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackenzie</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nuki</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hallas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hawkey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ralston</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Caterina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Findlay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Perez-Ruiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJV</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>TM</given-names>
              </name>
              <collab>FAST Study Group</collab>
            </person-group>
            <article-title>Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Nov</month>
            <day>28</day>
            <volume>396</volume>
            <issue>10264</issue>
            <fpage>1745</fpage>
            <page-range>1745-1757</page-range>
            <pub-id pub-id-type="pmid">33181081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r145">
          <label>145</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>58</volume>
            <issue>12</issue>
            <fpage>2122</fpage>
            <page-range>2122-2129</page-range>
            <pub-id pub-id-type="pmid">31098635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r146">
          <label>146</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.</article-title>
            <source>Rheumatol Int</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-281</page-range>
            <pub-id pub-id-type="pmid">36346443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r147">
          <label>147</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.</article-title>
            <source>Clin Cardiol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>44</volume>
            <issue>7</issue>
            <fpage>907</fpage>
            <page-range>907-916</page-range>
            <pub-id pub-id-type="pmid">34013998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r148">
          <label>148</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghang</surname>
                <given-names>BZ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.</article-title>
            <source>RMD Open</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35732345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r149">
          <label>149</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Dell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Brophy</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palevsky</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Davis-Karim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pittman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Terkeltaub</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cannella</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>England</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Helget</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management.</article-title>
            <source>NEJM Evid</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">35434725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r150">
          <label>150</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Disease in Gout and the&#x000a0;Protective Effect of Treatments Including Urate-Lowering Therapy.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>531</fpage>
            <page-range>531-541</page-range>
            <pub-id pub-id-type="pmid">30868398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r151">
          <label>151</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubreuil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rho</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol initiation and all-cause mortality in the general population.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>74</volume>
            <issue>7</issue>
            <fpage>1368</fpage>
            <page-range>1368-72</page-range>
            <pub-id pub-id-type="pmid">24665118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r152">
          <label>152</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luk</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Kestenbaum</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol and mortality in hyperuricaemic patients.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>804</fpage>
            <page-range>804-6</page-range>
            <pub-id pub-id-type="pmid">19447769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r153">
          <label>153</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Tsay</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study.</article-title>
            <source>J Rheumatol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>9</issue>
            <fpage>1694</fpage>
            <page-range>1694-701</page-range>
            <pub-id pub-id-type="pmid">26077411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r154">
          <label>154</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-78</page-range>
            <pub-id pub-id-type="pmid">27165177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r155">
          <label>155</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vargas-Santos</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.</article-title>
            <source>JAMA Intern Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>178</volume>
            <issue>11</issue>
            <fpage>1526</fpage>
            <page-range>1526-1533</page-range>
            <pub-id pub-id-type="pmid">30304329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r156">
          <label>156</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>133</fpage>
            <page-range>133-139</page-range>
            <pub-id pub-id-type="pmid">27296322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r157">
          <label>157</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cheetham</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.</article-title>
            <source>J Rheumatol</source>
            <year>2014</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>955</fpage>
            <page-range>955-62</page-range>
            <pub-id pub-id-type="pmid">24692523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r158">
          <label>158</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.</article-title>
            <source>J Rheumatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>11</issue>
            <fpage>2143</fpage>
            <page-range>2143-8</page-range>
            <pub-id pub-id-type="pmid">26428209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r159">
          <label>159</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>76</volume>
            <issue>10</issue>
            <fpage>1669</fpage>
            <page-range>1669-1678</page-range>
            <pub-id pub-id-type="pmid">28584186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r160">
          <label>160</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schindel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liberman</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Pinkhas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Calciuric effect of probenecid in gouty patients.</article-title>
            <source>Isr J Med Sci</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>377</fpage>
            <page-range>377-9</page-range>
            <pub-id pub-id-type="pmid">6853140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r161">
          <label>161</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlesinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yasothan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pegloticase.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-8</page-range>
            <pub-id pub-id-type="pmid">21193861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r162">
          <label>162</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sundy</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Baraf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Yood</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Gutierrez-Urena</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Treadwell</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Mellado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Maroli</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Waltrip</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Hamburger</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.</article-title>
            <source>JAMA</source>
            <year>2011</year>
            <month>Aug</month>
            <day>17</day>
            <volume>306</volume>
            <issue>7</issue>
            <fpage>711</fpage>
            <page-range>711-20</page-range>
            <pub-id pub-id-type="pmid">21846852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r163">
          <label>163</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baraf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Yood</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Mellado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ottery</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sundy</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Long-term safety of pegloticase in chronic gout refractory to conventional treatment.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2013</year>
            <month>Sep</month>
            <day>01</day>
            <volume>72</volume>
            <issue>9</issue>
            <fpage>1469</fpage>
            <page-range>1469-74</page-range>
            <pub-id pub-id-type="pmid">23144450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r164">
          <label>164</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keenan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2022</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>1006</fpage>
            <page-range>1006-1010</page-range>
            <pub-id pub-id-type="pmid">35238750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r165">
          <label>165</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pillinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Toprover</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>97</volume>
            <issue>7</issue>
            <fpage>1345</fpage>
            <page-range>1345-1362</page-range>
            <pub-id pub-id-type="pmid">35787862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r166">
          <label>166</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>458</fpage>
            <page-range>458-462</page-range>
            <pub-id pub-id-type="pmid">28846182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r167">
          <label>167</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doehner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Salsali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaempfer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brueckmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.</article-title>
            <source>Eur Heart J</source>
            <year>2022</year>
            <month>Sep</month>
            <day>21</day>
            <volume>43</volume>
            <issue>36</issue>
            <fpage>3435</fpage>
            <page-range>3435-3446</page-range>
            <pub-id pub-id-type="pmid">35788657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r168">
          <label>168</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fralick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Patorno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.</article-title>
            <source>Ann Intern Med</source>
            <year>2020</year>
            <month>Feb</month>
            <day>04</day>
            <volume>172</volume>
            <issue>3</issue>
            <fpage>186</fpage>
            <page-range>186-194</page-range>
            <pub-id pub-id-type="pmid">31931526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r169">
          <label>169</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berman</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Clues in the eye: ocular signs of metabolic and nutritional disorders.</article-title>
            <source>Geriatrics</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>34</fpage>
            <page-range>34-6, 43-4</page-range>
            <pub-id pub-id-type="pmid">7601360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r170">
          <label>170</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karlson</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study.</article-title>
            <source>Arch Intern Med</source>
            <year>2005</year>
            <month>Apr</month>
            <day>11</day>
            <volume>165</volume>
            <issue>7</issue>
            <fpage>742</fpage>
            <page-range>742-8</page-range>
            <pub-id pub-id-type="pmid">15824292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r171">
          <label>171</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roubenoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klag</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Seidler</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Incidence and risk factors for gout in white men.</article-title>
            <source>JAMA</source>
            <year>1991</year>
            <month>Dec</month>
            <day>04</day>
            <volume>266</volume>
            <issue>21</issue>
            <fpage>3004</fpage>
            <page-range>3004-7</page-range>
            <pub-id pub-id-type="pmid">1820473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r172">
          <label>172</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>P&#x000e9;trilli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mayor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tardivel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tschopp</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gout-associated uric acid crystals activate the NALP3 inflammasome.</article-title>
            <source>Nature</source>
            <year>2006</year>
            <month>Mar</month>
            <day>09</day>
            <volume>440</volume>
            <issue>7081</issue>
            <fpage>237</fpage>
            <page-range>237-41</page-range>
            <pub-id pub-id-type="pmid">16407889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22376.r173">
          <label>173</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Gout and comorbidity: a nominal group study of people with gout.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2017</year>
            <month>Sep</month>
            <day>15</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>204</fpage>
            <pub-id pub-id-type="pmid">28915838</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
